WO2002043649A2 - Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof - Google Patents

Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof Download PDF

Info

Publication number
WO2002043649A2
WO2002043649A2 PCT/IL2001/001088 IL0101088W WO0243649A2 WO 2002043649 A2 WO2002043649 A2 WO 2002043649A2 IL 0101088 W IL0101088 W IL 0101088W WO 0243649 A2 WO0243649 A2 WO 0243649A2
Authority
WO
WIPO (PCT)
Prior art keywords
microorganism
probiotic composition
volatile fraction
plant extract
probiotic
Prior art date
Application number
PCT/IL2001/001088
Other languages
French (fr)
Other versions
WO2002043649A3 (en
WO2002043649A8 (en
Inventor
Mark Olshenitsky
Genadi Buchman
Original Assignee
The Bio Balance Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/725,846 external-priority patent/US6500423B2/en
Priority to AU2002221004A priority Critical patent/AU2002221004B2/en
Priority to JP2002545628A priority patent/JP4410992B2/en
Priority to KR10-2003-7007337A priority patent/KR20030082549A/en
Priority to AU2100402A priority patent/AU2100402A/en
Priority to BR0116178-4A priority patent/BR0116178A/en
Priority to NZ526748A priority patent/NZ526748A/en
Priority to EP01998302A priority patent/EP1343370A4/en
Application filed by The Bio Balance Corp. filed Critical The Bio Balance Corp.
Priority to IL15621301A priority patent/IL156213A0/en
Priority to CA002430292A priority patent/CA2430292A1/en
Priority to US10/432,346 priority patent/US7504251B2/en
Priority to MXPA03004851A priority patent/MXPA03004851A/en
Publication of WO2002043649A2 publication Critical patent/WO2002043649A2/en
Publication of WO2002043649A3 publication Critical patent/WO2002043649A3/en
Publication of WO2002043649A8 publication Critical patent/WO2002043649A8/en
Priority to AU2007201690A priority patent/AU2007201690A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/84—Flavour masking or reducing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.
  • VF volatile fraction
  • the gastrointestinal (GI) tract microflora contributes significantly to the health and well being of an individual. It is well known that the microflora is a complex and diverse population of microorganisms, which may have both beneficial and harmful effects on the individual. Under normal gestation conditions, the fetus in utero is sterile, but on passage through the vagina during birth it acquires microorganisms resulting in the formation of a gut microflora. The final indigenous gut microflora which stabilizes in the gut is a very complex collection of over one thousand different types of microorganisms, consisting of about 400 different types of bacteria [Fuller R. J. Applied Bacteriology 66:365-378 (1989)].
  • the composition of the gut microflora is determined by both host and microbial factors, and although there are a lot of bacteria which can survive and grow in the GI tract, there are many which cannot. In addition, the surviving organisms have to avoid the effect of peristalsis which normally flushes out the bacteria with the food. This may be achieved by the bacteria immobilizing themselves by attachment to the gut wall, and/or by multiplying at a rate that exceeds the rate of removal by peristalsis. In general, the presence of gut microflora is symbiotic as the microflora not only assists in disintegrating some undigestable foods, it also protects the individual from infections caused by pathogens. This latter phenomenon has been described under such names as 'bacterial antagonism', 'bacterial interference', 'barrier effect', 'colonization resistance', 'competitive exclusion' and many others.
  • the gut protective microflora is very stable. However, it is less effective in the young, elderly and the compromised patient. Further, it can be influenced by certain dietary and environmental factors, the three most important being excessive hygiene, antibiotic therapy and stress.
  • Probiotics Under conditions where the balance of the gut microflora is adversely affected, probiotics become of potential value in restoring the gut microflora and enabling the individual host to return to normal.
  • Probiotics are a class of microorganisms defined as live microbial organisms that beneficially affect the animal and human hosts.
  • the beneficial effects include improvement of the microbial balance of the intestinal microflora or improving the properties of the indigenous microflora.
  • the beneficial effects of probiotics may be mediated by a direct antagonistic effect against specific groups of organisms, resulting in a decrease in numbers, by an effect on their metabolism or by stimulation of immunity.
  • Probiotics may suppress viable counts of an undesired organism by producing antibacterial compounds, by competing for nutrients or for adhesion sites.
  • 095/16461 describes a probiotic composition of anaerobic bacteria effective in controlling or inhibiting Salmonella colonization in domesticated animals.
  • the probiotic composition includes populations or cultures of 29 substantially biologically pure bacteria, inter alia, E. coli.
  • the suppression of the pathogen by the probiotic composition described in this PCT publication requires the combined action of a large number of bacterial strains.
  • 097/35596 describes the administration of a freshly prepared probiotic mixture obtained by mixing a powder containing Lactobacillus reuteri, Lactobacillus acidophilus and Bifidobacterium infantis with a liquid.
  • the mixture is described to be effective in preventing infectious diarrhea or diarrhea caused by antibiotic therapy in humans.
  • the freeze-dried live bacteria are, however, in anabiotic state.
  • the need to wet the microorganism before administration, in order to reinstate its vitality, is a disadvantage, since normally many bacteria do not survive the re-hydration.
  • the surviving organisms are not immediately metabolically active, and cannot survive the extreme, acidic conditions of the stomach.
  • the rate of their removal from the gut may exceed the rate of reinstation of viability, resulting in minimal or no beneficiary effect.
  • W098/26787 describes the enhancement of a resident population of lactic acid-producing microorganisms, preferably lactobaccillii, in the GI tract of an animal by providing the same with ⁇ -glucan, optionally in combination with prebiotic and/or probiotic microorganisms.
  • W097/34591 also describes the enhancement of resident population of microorganisms, or the suppression of the undesired resident population at a selected site of the GI tract of an individual, by providing the individual with a selected modified or unmodified starch or mixtures thereof, which act as carrier for one or more probiotic microorganisms and as a growth or maintenance medium for the microorganisms.
  • the probiotic elements are bound to the carrier in a manner so as to protect the microorganisms during passage to the large bowel or other regions of the GI tract.
  • Microorganisms are used in a variety of industrial processes. These processes can be divided into continuous processes and batch processes.
  • continuous processes such as a continuous aerobic or anaerobic fermentation line, used for the production of a variety of fermentation products, including, for example, ethanol and methanol
  • a fermentable raw material is continuously fed into the line and the fermentive product is continuously collected from the line, in a controlled fashion, such that the microorganism population in the line is sustained throughout the process.
  • batch processes such as, but not limited to, batch aerobic or anaerobic fermentation, biodegradation of oil in, for example, oil spills, and the like, a fermentable raw material is mixed with a population of microorganism(s) so as to instate fermentation.
  • microorganisms including probiotic microorganisms and microorganisms useful in a variety of industrial applications, could be maintained viable and in a metabolically active form for long periods of time .
  • a single species of a non-pathogenic probiotic microorganism derived from E. coli is, alone, capable of restoring normal GI flora of man and of a variety of mammals and avians. It has also been surprisingly found that this microorganism, as well as other microorganisms, could be preserved for long periods of time, in a viable and metabolically active form, in a formulation comprising water solution of volatile fraction(s) of various plant extracts.
  • a probiotic composition comprising the probiotic organism suspended in the formulation was found to be effective in the treatment and prevention of various gastrointestinal disorders. It has further been unexpectedly found that the formulation per se is effective as a body weight gain enhancer and as an immuno-stimulator in mammals and avians.
  • Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799).
  • a probiotic composition comprising viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) and a formulation for maintaining viability of the Escherichia coli strain.
  • the probiotic composition preferably further comprising at least one flavouring agent.
  • the formulation includes at least one volatile fraction (VF) of a plant extract prepared by steam distillation of a plant (e.g., beet, dill, parsley or grapefruit) extract under reduced pressure and at a bath temperature preferably not exceeding 38 °C.
  • the probiotic composition of the present invention may be identified for preventing or treating gastro-enteric infections or disorders, maintaining or reinstating normal gastro-intestinal microflora, preventing or treating diarrhea, preventing or treating gastro-enteric infection caused by an enteric pathogen, such as a Gram negative bacterium or Gram positive bacterium, preventing or treating gastro-enteric Salmonella infection, preventing or treating infectious diarrhea, caused by, for example C. difficile, Salmonella, particularly S. Shigella, Campylobacter, E. coli, Proteus,, Pseudomonas or Clostridium, chronic diarrhea or diarrhea resulting from antibiotic therapy, radiotherapy or chemotherapy, and/or for normalizing the physiological activity of the gastrointestinal tract.
  • enteric pathogen such as a Gram negative bacterium or Gram positive bacterium
  • gastro-enteric Salmonella infection preventing or treating infectious diarrhea, caused by, for example C. difficile, Salmonella, particularly S. Shigella, Campylobacter, E. coli, Proteus,, Pseudom
  • a formulation comprising at least one volatile fraction (VF) of a plant extract, the volatile fraction is prepared by steam distillation of the plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
  • the plant extract is preferably obtainable from a plant organ selected from the group consisting of leaves, stems, roots and fruit.
  • the plant can be a vegetable, such as soy bean, alfalfa, garlic, beet and cabbage, or a herb, such as parsley, mint and dill.
  • the formulation may further include a beehive product, such as, but not limited to, propolis.
  • the formulation can serve as a veterinary feed or food additive for enhancing animal weight gain in a recipient. It can also serve to preserve viable bacteria as is further described herein.
  • a process of preparing a volatile fraction of a plant comprising the steps of (a) grinding a plant derived material to give a plant biomass; (b) mixing the plant biomass with water and stirring at ambient temperature; (c) steam distilling the mixture obtained in step (b) under reduced pressure and at a bath temperature not exceeding 38°C; and (d) collecting volatile fraction obtained from the steam distillation.
  • the reduced pressure is of 5-10 mbar.
  • a therapeutic formulation containing the volatile fraction of a plant is also disclosed and may be prepared by mixing at least one volatile fraction (VF) of a plant extract with physiologically or veterinary acceptable additives, carriers or diluents.
  • VF volatile fraction
  • the volatile fraction is prepared by steam distillation of the plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
  • a probiotic composition comprising (a) an effective amount of at least one viable probiotic microorganism having a beneficial biological or therapeutic activity in the gastrointestinal tract; and (b) at least one volatile fraction (VF) of a plant extract preferably prepared as described herein.
  • the probiotic microorganism can be E. coli, preferably, strain BU-230-98, ATCC Deposit No.
  • a composition comprising (a) at least one microorganism, such as, Escherichia spp., Alcaligenes spp., Arthrobacter spp., Bifidobacterium spp., Lactobacillus spp., Lactococcus spp., Nitrosomonas spp. and Pseudomonas spp.; and (b) at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months, preferably at least 3-6 months, more preferably 6-12 months or more at room temperature.
  • VF volatile fraction
  • a process of growing Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 comprising the step of seeding a starter cloture of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) into a growth media and growing the Escherichia coli strain up to optical density of 15-30 at 650 nm.
  • a process of manufacturing a probiotic composition comprising the step of suspending viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) in a formulation for maintaining viability of the Escherichia coli strain.
  • the formulation includes at least one volatile fraction (VF) of a plant extract, prepared, preferably by steam distillation of the plant extract under reduced pressure and at a bath temperature not exceeding 38 °C, obtained from, for example, a plant organ selected from the group consisting of leaves, stems, roots and fruit, either a vegetable and a herb, such as soy bean, parsley, mint, dill, alfalfa, garlic, beet or cabbage.
  • VF volatile fraction
  • a process of preparing a probiotic composition comprising the step of suspending an effective amount of at least one viable probiotic microorganism having a beneficial biological or therapeutic activity in the gastrointestinal tract in an formulation containing at least one volatile fraction (VF) of a plant extract.
  • VF volatile fraction
  • a process of preparing a composition including viable microorganisms comprising the step of suspending at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature.
  • the microorganism can be, for example, Escherichia spp., Alcaligenes spp., Arthrobacter spp., Bifidobacterium spp., Lactobacillus spp., Lactococcus spp., Nitrosomonas spp. or Pseudomonas spp.
  • a dispenser of microorganisms comprising a reservoir and a dispensing mechanism being connected thereto, the reservoir housing at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature.
  • VF volatile fraction
  • a method of biocontrol of an organism comprising the step of spreading in an endemic area at least one viable microorganism capable of biocontrolling the organism, the at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature.
  • VF volatile fraction
  • a method of eliminating an oil pollution comprising the step of spreading in a polluted area at least one viable microorganism capable of degrading oil, the at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature.
  • VF volatile fraction
  • a method of restoring organic fumes degrading microorganism population in a biofilter comprising the step of dispensing onto the filter at least one viable microorganism capable of degrading organic fumes, the at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature.
  • VF volatile fraction
  • a method of preparing a starter for a fermentation process comprising the step of growing a sufficient amount of a starter microorganism and suspending the starter microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the starter microorganism for at least 2 months at room temperature.
  • VF volatile fraction
  • FIG. 1 is a schematic depiction of a dispenser according to the present invention.
  • the present invention is of (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.
  • VF volatile fraction
  • the present invention relates to a probiotic microorganism being a non-pathogenic bacterium derived from E. coli, having a beneficial physiological and/or therapeutic activity in, for example, the GI tract and deposited at the ATCC under deposit No. 202226 and at DSMZ under deposit
  • Probiotic is used herein as an adjective to describe an isolated bacteria having the property of inhibiting the growth of at least one pathogen.
  • the test of an inhibition used herein was an in vitro test on solid medium in which culture supernatants of candidate isolated bacteria were observed for their property of inhibiting the growth of a pathogen when applied to the surface of the solid medium.
  • a paper disc impregnated with the culture supernatant of a candidate probiotic strain was placed on the surface of an agar plate seeded with the pathogen.
  • Probiotic bacterial supernatants caused a ring of clear agar or of reduced growth density indicating inhibition of the pathogen in the vicinity of the disc.
  • the probiotic bacteria of the present invention may serve as a food or feed additive, so as to provide food or feed product supplemented with viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799).
  • a food product of the present invention may further include at least one milk derived substance and may be selected from the group consisting of a cheese and a yogurt.
  • the present invention further relates to a formulation comprising at least one volatile fraction (VF) of a plant extract, the volatile fraction being prepared by distillation of the plant extract under reduced pressure and at a bath temperature typically not exceeding 38 °C.
  • VF volatile fraction
  • the plant matter from which the volatile fraction may be obtained may be any suitable plant part such as fruit, leaf, stem or root.
  • Many plants are suitable as a source for the volatile fractions, for example apple, citrus, soy bean, beet, cabbage, garlic and alfalfa, as well as herbs such as parsley, mint and dill.
  • the formulations of the invention may optionally further comprise a suitable amount of a volatile fraction of an apicultural product such as honey, propolis or other beehive product, which may be prepared in the same manner as described herein for obtaining volatile fractions from plant extracts.
  • the formulation itself may be used as a food/feed additive. It has been found by the inventors to have a weight gain enhancing activity and it constitutes an aspect of the invention.
  • the animal weight gain enhancing formulation or feed additive comprises distilled water and volatile fractions of alfalfa, soy beans, beet and dill, preferably at a volume ratio of the volatile fractions of 2:8:1 :4.
  • a formulation or feed additive of the present invention comprises distilled water and volatile fractions of carrot, beet, dill and grapefruit (1 part each) per 100 parts of water.
  • a formulation or food additive of the present invention comprises distilled water and volatile fractions of beet, dill and parsley (1 part each) per 100 parts of water.
  • the invention relates to a composition comprising the above formulation of the invention and at least one viable microorganism, either a probiotic organism having a therapeutic or beneficial biological activity in, for example, the GI tract of human and/or animal, to thereby provide a probiotic composition, or an organism having industrial applications, to thereby provide a composition of industrial applicability.
  • probiotic and industrial compositions of the invention stems from the fact that they are liquid preparations. Being under biologically active conditions, the formulation serves also as a supportive medium for living bacteria, as opposed to lyophilized formulations where the bacteria are in an anabiotic condition.
  • the probiotic composition of the invention for example, is active immediately following oral administration, beginning with the upper portion of the GI tract, where primary effects of the majority of intestinal pathogens take place, causing development of adverse gastro-enteric syndromes.
  • the probiotic compositions of the invention may also be used as body weight-increasing preparations or food/feed additives.
  • the industrial composition of the invention can be used to efficiently reinstate a population of microorganisms of industrial applicability.
  • probiotic bacteria other than such belonging to the strain BU-230-98 (ATCC Deposit No. 202226, also deposited at the DSM under No. 12799), may be used with the plant material derived formulation of the invention.
  • Such probiotic bacteria have a very broad spectrum of antagonistic activity. They also belong to the same phylogenetic group of the majority of intestinal pathogens and share the same systems of survival. Therefore, the suppression and exclusion of intestinal pathogens may include many different mechanisms, for example, secretion of antagonistic material, competition for utilization of nutrients and competition for adhesion receptors. Thus, any non-pathogenic bacteria which comply with these criteria, may be used in the probiotic compositions of the invention.
  • the probiotic compositions of the invention may be used for preventing or treating gastro-enteric infections.
  • Term 'gastro-enteric infection' is to be taken to mean any infection caused an enteric pathogen, including, inter alia, Gram negative and Gram positive bacteria.
  • the formulations and probiotic compositions of the invention may be instrumental in prophylaxis of also GI infections caused by yeast, viruses and protozoa.
  • the term 'therapeutically effective amount' or 'effective amount' for purposes herein is the amount determined by such considerations as are known in the art. The amount must be sufficient to enable the efficient restoration of the GI microflora thus leading to the normalization of the function of the GI tract.
  • the probiotic composition for preventing the development of gastro-enteric infections comprises the formulation of the invention made from distilled water and volatile fractions of alfalfa, soy beans, beet, dill and mint as defined herein, at a volume ratio of, e.g., 5:1:5:15:1, and a therapeutically effective amount of a probiotic bacteria such as E. coli ATCC Deposit No. 202226 (identical with DSM 12799) or any other probiotic bacteria.
  • a probiotic bacteria such as E. coli ATCC Deposit No. 202226 (identical with DSM 12799) or any other probiotic bacteria.
  • a specific example for an gastro-enteric infection is that caused by Salmonella and the invention is of particular advantage in preventing or treating gastro-enteric infections caused thereby.
  • the food additive or formulation of the invention alone or in combination with an effective amount of a probiotic microorganism, such as the E. coli strain ATCC Deposit No. 202226 (identical with DSM 12799), may be used for treating or preventing infectious diarrhea, chronic diarrhea or diarrhea caused by antibiotic or chemo-therapy.
  • such a probiotic composition for treating diarrhea may comprise distilled water and volatile fractions of alfalfa, soy beans, beet, dill and mint at a volume ratio of, e.g., 5:1:5:15:1, and a therapeutically effective amount of the ATCC No.
  • the infectious diarrhea may be caused by numerous factors, for example, by a microorganism selected from C. difficile, Salmonella, particularly S. Shigella, Campylobacter, E. coli, Proteus, Pseudomonas, Clostridium, enteric Staphylococcus. These are but few of many infecting agents.
  • compositions of the invention may be used for effectively restoring the GI microflora in a subject in need of such treatment which leads to the normalization of the function of the GI tract.
  • Such compositions may include, for example, distilled water and volatile fractions of alfalfa, soy bean, beet, dill, mint, parsley and cabbage, preferably at a ratio of volatile fractions of, e.g., 1 :5:5:2:2:1, and a therapeutically effective amount of the probiotic bacteria ATCC Deposit No. 202226 (DSM 12799).
  • probiotic compositions of the invention comprising at least one probiotic bacteria having a therapeutic effect in, for example, the GI tract
  • Other purposes for which the probiotic compositions of the invention, comprising at least one probiotic bacteria having a therapeutic effect in, for example, the GI tract include alleviation of lactose intolerance in subjects suffering from lactose intolerance, treatment of enterocolitis, treatment of constipation, for reduction of cholesterol levels in the blood, for treatment of dyspeptic symptoms, and/or for stimulation of the immune system in subjects suffering from an immune system disorder, which may be an immune disorder caused by immuno-suppressive therapy.
  • the invention relates to a process for preparing a volatile fraction of a plant extract, which process comprises the steps of: (a) grinding plant derived matter to obtain a plant biomass; (b) mixing the plant biomass obtained in step (a) with water at a weight proportion of preferably 3 parts water to 1 part of the plant biomass and stirring the same for at least 2 hours at ambient temperature; (c) distilling the mixture obtained in step (b) under reduced pressure and at a bath temperature preferably not exceeding 38 °C; and (d) collecting the volatile fraction obtained from the steam distillation, which fraction may further be diluted in a suitable buffer.
  • the volatile fraction of the invention may be mixed with water to give the food/feed additive or formulation of the invention.
  • the food/feed additive or formulation of the invention may also be prepared by mixing more than one plant volatile fraction obtained by the process of the invention. This mixture may be further mixed with water.
  • the volatile fractions may be prepared from may any suitable fruit, vegetable, leaf, stem or root of a plant.
  • the plant can be, for example, apple, citrus fruit, soy bean, beet, garlic, cabbage or alfalfa, or a herb such as parsley, mint or dill.
  • the formulation may further comprise volatile fractions from apicultural products such as honey or propolis or other beehive products. These volatile fractions may be prepared in the same manner of the plant extract volatile fractions.
  • the distillation step is preferably carried out under reduced pressure of 5-10 mbar.
  • the food/feed additive or formulation of the invention may be further combined with at least one probiotic or industrial agent, to give the probiotic or industrial compositions of the invention.
  • the process of preparation of the invention may also further comprise the step of suspending at least one viable probiotic or industrial microorganism in the volatile fraction obtained in said step (d) or in a mixture of such volatile fractions obtained as described above.
  • the probiotic microorganism suspended may be the novel bacterium of the invention, derived from E. coli and deposited at the ATCC under Deposit No. 202226 (and at DSM under deposit No. 12799).
  • the invention relates to the use of a volatile fraction (VF) of a plant extract in the preparation of a food/feed additive, wherein the VF is prepared by steam distillation of said plant extract or from apiculture product extract such as honey or propolis at a bath temperature not exceeding 38 °C.
  • VF volatile fraction
  • An additional aspects of the invention include a process of preparing a composition including viable microorganisms.
  • the process is effected by suspending at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract.
  • the formulation is selected so as to sustain viability of the microorganism(s) for at least 2 months at room temperature.
  • the microorganism of choice may be probiotic or have industrial applicability.
  • Organisms which can be maintained in a formulation of the present invention include Escherichia spp., Alcaligenes spp., Arthrobacter spp., Bifidobacterium spp., Lactobacillus spp., Lactococcus spp., Nitrosomonas spp.
  • Dispenser 10 includes a reservoir 12 and a dispensing mechanism 14 connected thereto.
  • Reservoir 12 houses at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract.
  • the formulation is selected so as to sustain viability of the microorganism(s) for at least 2 months at room temperature.
  • Reservoir 12 may be refrigerated, say to about 2-20 °C, preferably to about 4 °C.
  • Dispenser 10 may be an airborne dispenser, so as to allow dispersion of pest control bioagents.
  • the dispenser may be hand held. In any case, the dispenser may be designed to automatically dispense a predefined volume therefrom, e.g., periodically.
  • dispenser 10 may include a programmable or preset control mechanism 16, valves 18, etc.
  • the present invention provides a method of biocontrol of an organism which is effected by spreading in an endemic area at least one viable microorganism capable of biocontrolling the organism.
  • the viable microorganism(s) are present in a formulation containing at least one volatile fraction (VF) of a plant extract selected so as to sustain viability of said at least one microorganism(s) for at least 2 months at room temperature.
  • the present invention provides a method of eliminating an oil pollution which is effected by spreading in a polluted area at least one viable microorganism capable of degrading oil, such as Pseudomonas spp.
  • the viable microorganism(s) is present in a formulation containing at least one volatile fraction (VF) of a plant extract selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
  • the present invention provides a method of restoring organic fumes degrading microorganism population in a biofilter by dispensing onto the filter at least one viable microorganism, such as Pseudomonas spp., Nitrosomonas spp., or Arthrobacter spp. capable of degrading organic fumes.
  • viable microorganism(s) is present in a formulation containing at least one volatile fraction (VF) of a plant extract selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
  • VF volatile fraction
  • a method of preparing a starter for a fermentation process by growing a sufficient amount of a starter microorganism, such as, Lactococcus spp., Escherichia spp., Bifidobacterium spp., Lactobacillus, Lactococcus spp. or Pseudomonas spp. and suspending the starter microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract selected so as to sustain viability of said starter microorganism for at least 2 months at room temperature.
  • a starter microorganism such as, Lactococcus spp., Escherichia spp., Bifidobacterium spp., Lactobacillus, Lactococcus spp. or Pseudomonas spp.
  • each "volatile fraction" was prepared from a single kind of vegetable and used in different dilution to prepare different mixtures for various purposes.
  • Example 2 Isolation and growth of the probiotic organism E. coli ATCC Deposit No. 202226
  • the probiotic organism E. coli (deposited at the ATCC under No. 202226 on May 3, 1999 and at the DSM under No. 12799 on May 4, 1999) was isolated from E. coli M-17 by sequential transfer of isolates initiating from long term (2 months) survivors preserved in a formulation containing volatile fractions of plant derived material as is described under Example 1 above at 37 °C and selecting for isolates capable of competition with pathogens as is further detailed below.
  • the probiotic organism E. coli (deposited at the ATCC under No.
  • Additional nutrients (yeast extract - 1 g/liter, Soy peptone - 2.5 g/liter and glucose - 90 g/liter) were continuously added following the growth of the culture in such a way that the glucose concentration in the fermentation broth was kept at a level of 2 g/liter.
  • the pH of the fermentation broth was kept neutral by the continuous addition of 4N NH4OH.
  • Culturing was carried out at 30 °C in a standard fermentation vessel with aeration of 0.5 wm for 16 hours, when the growth became confluent. This procedure resulted in 10 -10 cells/ml.
  • the E. coli cells were harvested by centrifugation, resuspended in saline and re-precipitated.
  • the microbial biomass could be kept in saline in the refrigerator for 48 hours without loosing viability.
  • Example 3 Preparation of food/feed additive formulation for the accelerated increase of body weight in mammals and avians
  • the mixture contained volatile fractions of: alfalfa - 50 ml/liter, soy beans - 200 ml/liter, beet - 25 ml/liter and dill - 100 ml/liter, prepared as described under Example 1 above. The balance was made up by the distilled water.
  • the mixture contained volatile fractions of: alfalfa - 50 ml/liter, soy beans - 10 ml/liter, beet - 50 ml/liter, dill - 50 ml/liter, mint - 20 ml/liter, parsley - 20 ml/liter and cabbage - 10 ml/liter, prepared as described under Example 1 above.
  • the balance was made up by distilled water.
  • E. coli (ATCC 202226) cells (Example 2) were suspended in the mixture at a cell ⁇ ccoonncceennttrraatitioonn ooff 1100 cceellllss//mmll..
  • N NaCl (e.g., 4-10 g/liter) may be optionally added for the improvement of taste.
  • coli (ATCC 202226) cells (Example 2) were suspended in ⁇ tthhee mmiixxttuurree aatt aa cceellll ccoonncceennttrraattiioonn ooff 1100 cceellllss//mml.
  • NaCl (4-10 g/liter) may be optionally added for the improvement of the taste
  • Salmonella typhymirium (ATCC 14028) Petri plates containing Modified Brilliant Green Agar, a selective growth medium for Salmonella, were inoculated with S. typhimirium. A 9 mm diameter well was made in the agar. A volume of the food supplement (Example 4) was deposited in each well, and the plates were incubated for 24 hours at 35 °C. The same was repeated, but instead of the food supplement, the fluid obtained by its filtration through a microbiological filter membrane (pore size of 0.45 ⁇ m) was deposited in the well.
  • a microbiological filter membrane pore size of 0.45 ⁇ m
  • Antagonistic activity ofE. coli ATCC 202226 as well as of its parent strain E. coli M-l 7 against Shigella sps.
  • Cultures of S. flexneri, S. sonnei, E. coli (ATCC 202226) and M-l 7 were grown separately on a Nutrient Agar for 18-20 hours at 37 °C. All the cultures were harvested in saline and diluted to an optical density of 10 Klett units. Aliquots of the diluted cultures of Shigella species (1 ml) alone or in combination with the diluted culture of E. coli (ATCC 202226) (1 ml) were seeded in ventilation-cup test tubes containing Nutrient Broth (5 ml).
  • CFU colony-forming units
  • Colibacterin Cold-dried preparation of live E. coli M-l 7 produced by BIOMED Ltd., Moscow, Russia, and recommended for use against diarrhea [Vidal Handbook: Pharmaceutical preparations in Russia (N.B. Nikolaeva, B.P. Alperovich and V.N. Sovinov, Eds.) AstraPharmService, 1997, Moscow, p. 275].
  • Group I contained 48 patients with peptic ulcer disease who developed GI disorders after antibiotic treatment against H. pylori.
  • Group II contained 22 patients that developed GI disorders following antibiotic treatment of pneumonia.
  • the food supplement (5 ml) was given 3 times a day before meals for 7 days. In both groups symptoms of diarrhea disappeared in 2-3 days in all the patients. After the administration of the supplement, complete normalization of intestinal microflora was observed in 84.5 % of the patients. It was demonstrated by a dramatic increase in lactobacilli and Bifidobacteria, reduction on the general count of E. coli, complete disappearance of the hemolytic E. coli and other pathogens such as Staphylococci, Proteus vulgaris and even Candida sps. In the remaining 15.5 % of the patients, a significant improvement was observed.
  • Example 11 Application of the food supplement (Example 5) in patients with late radiation enterocolitis
  • the food supplement (10 ml, 3 times a day for 14 days, 30 minutes before the meals) was given to 24 patients with womb, colon and gastric cancer that developed enterocolitis following radiation therapy or a combination of radiation and chemotherapy. Prior to the use of the food supplement, all patients complained about frequent and painful desire to defecate, liquid stool (4-12 times a day) appearance of mucous (9 cases) and blood (3 cases) in the stool.
  • Example 13 Application of the food/feed additive (Example 3) for accelerated weight increase in healthy piglets Healthy piglets were administrated 3 ml per os of the food/feed additive per piglet per day until weaning. The group receiving the feed additive gained weight at weaning on the average 1.0 kg per piglet more than the control group.
  • Example 16 Application of the feed additive (Example 4) in healthy calves
  • Example 17 Application of the feed additive (Example 6) in calves showing diarrhea
  • Calves developing diarrhea were given daily 10 ml of the feed additive per animal with milk during 3-5 days.
  • the diarrhea was caused by virus.
  • These calves were treated with antibiotics with poor results.
  • Example 18 Application of the feed additive (Example 6) in healthy lambs and goat kids
  • the feed additive was tested in a herd suffering from pathogenic E. coli infections. In the year preceding the experiment, about 90 from 120 lambs and goat kids died from diarrhea. Treatment with antibiotics was ineffective, since the disease developed suddenly and with fast mortality. Lambs and goat kids developing diarrhea were given daily 5 ml of the feed additive per animal with milk during 3-5 days. A matching group of animals was treated, as normally recommended, with antibiotics. The symptoms of diarrhea disappeared within 1-2 days in about 90 % of the lambs and goat kids receiving the feed additive. Their further development appeared normal. The control group receiving antibiotics (gentamycin) showed much poorer results. Diarrhea in this group persisted, calling for repeated treatment with antibiotics. The development of the control group was severely retarded.
  • Example 20 Application of the feed additive (Example 5) in poultry
  • the feed additive was added to the drinking water with the average uptake of 0.01 ml of the additive per day per chick during the breeding period (42-49 days).
  • An increase of 3.2 % in weight gain, accompanied by 4 % improvement in food conversion was noted in controlled trials in broilers.
  • mice Two-weeks-old C571B1 mice were divided into 4 groups of 10 animals in each. Mice were deprived water from 4:00 pm to 8:00 am and then given 15 ml of either water (groups 1 & 3) or the feed additive (groups 2 & 4). This treatment was repeated for 2 weeks. At the end of this treatment mice from groups 3 and 4 were subjected to laparotomy under ether narcosis. A cut of 1.5 cm was made in the abdominal wall. Irritation of intestine was carried out by a dry gause. All the mice were sacrificed 24 hours after laparatomy; spleens were excised.
  • Splenocytes were isolated and cultured on RPMI medium for 48-72 hours in the presence of phytohemagglutinin (PHA). In the group treated with the feed additive the proliferative activity of splenocytes reduced by laparotomy was recovered. Splenocytes proliferation induced by PHA:
  • Example 23 Application of the food additive (Example 4) in human; Evidence for immunostimulation A number of patients were operated for malignant tumors of womb, cervix, stomach, and intestine. The gynecological patients (20 patients) received follow-up radiotherapy; the abdominal patients (30 patients) received chemotherapy. About half of the patients received the food additive twice daily for the duration of therapy. In all patients receiving the food additive there was observed a significant immunostimulation, as expressed in:
  • T-lymphocytes O.G3 ⁇ 0.01 0.10 ⁇ 0.03 l.O ⁇ O.l 1.6--0.2
  • E. coli cells were dispersed in a formulation prepared as described under Example 1 above and was maintained for 6 months at room temperature. Both at the beginning and at the end of the 6 months period, samples derived from the dispersion were seeded at appropriate consecutive dilutions on nutrient broth agar plates. The number of colony forming units was determined for both samples. The concentration determined was lxlO 7 in both cases, showing the effect of the formulation in preserving microorganisms. The above experiment was performed in parallel with Pseudomonas putida, yielding the same results.

Abstract

The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.

Description

BACTERIAL STRAIN, PROCESSED PLANT EXTRACTS, COMPOSITIONS CONTAINING SAME, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC AND INDUSTRIAL
APPLICATIONS
FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.
Under normal conditions, the gastrointestinal (GI) tract microflora contributes significantly to the health and well being of an individual. It is well known that the microflora is a complex and diverse population of microorganisms, which may have both beneficial and harmful effects on the individual. Under normal gestation conditions, the fetus in utero is sterile, but on passage through the vagina during birth it acquires microorganisms resulting in the formation of a gut microflora. The final indigenous gut microflora which stabilizes in the gut is a very complex collection of over one thousand different types of microorganisms, consisting of about 400 different types of bacteria [Fuller R. J. Applied Bacteriology 66:365-378 (1989)]. The composition of the gut microflora is determined by both host and microbial factors, and although there are a lot of bacteria which can survive and grow in the GI tract, there are many which cannot. In addition, the surviving organisms have to avoid the effect of peristalsis which normally flushes out the bacteria with the food. This may be achieved by the bacteria immobilizing themselves by attachment to the gut wall, and/or by multiplying at a rate that exceeds the rate of removal by peristalsis. In general, the presence of gut microflora is symbiotic as the microflora not only assists in disintegrating some undigestable foods, it also protects the individual from infections caused by pathogens. This latter phenomenon has been described under such names as 'bacterial antagonism', 'bacterial interference', 'barrier effect', 'colonization resistance', 'competitive exclusion' and many others.
The gut protective microflora is very stable. However, it is less effective in the young, elderly and the compromised patient. Further, it can be influenced by certain dietary and environmental factors, the three most important being excessive hygiene, antibiotic therapy and stress.
Under conditions where the balance of the gut microflora is adversely affected, probiotics become of potential value in restoring the gut microflora and enabling the individual host to return to normal. Probiotics are a class of microorganisms defined as live microbial organisms that beneficially affect the animal and human hosts. The beneficial effects include improvement of the microbial balance of the intestinal microflora or improving the properties of the indigenous microflora. The beneficial effects of probiotics may be mediated by a direct antagonistic effect against specific groups of organisms, resulting in a decrease in numbers, by an effect on their metabolism or by stimulation of immunity. Probiotics may suppress viable counts of an undesired organism by producing antibacterial compounds, by competing for nutrients or for adhesion sites. Further, they may alter microbial metabolism by increasing or decreasing enzyme activity or they may stimulate the immune system by increasing antibody levels or increasing macrophage activity. 095/16461 describes a probiotic composition of anaerobic bacteria effective in controlling or inhibiting Salmonella colonization in domesticated animals. The probiotic composition includes populations or cultures of 29 substantially biologically pure bacteria, inter alia, E. coli. However, the suppression of the pathogen by the probiotic composition described in this PCT publication requires the combined action of a large number of bacterial strains. 097/35596 describes the administration of a freshly prepared probiotic mixture obtained by mixing a powder containing Lactobacillus reuteri, Lactobacillus acidophilus and Bifidobacterium infantis with a liquid. The mixture is described to be effective in preventing infectious diarrhea or diarrhea caused by antibiotic therapy in humans. The freeze-dried live bacteria are, however, in anabiotic state. The need to wet the microorganism before administration, in order to reinstate its vitality, is a disadvantage, since normally many bacteria do not survive the re-hydration. Moreover, the surviving organisms are not immediately metabolically active, and cannot survive the extreme, acidic conditions of the stomach. Furthermore, when administered to a recipient with diarrhea, the rate of their removal from the gut may exceed the rate of reinstation of viability, resulting in minimal or no beneficiary effect.
Preservation of viability and conservation of the activity of probiotic organisms by their formulation is the issue of numerous publications. W098/26787 describes the enhancement of a resident population of lactic acid-producing microorganisms, preferably lactobaccillii, in the GI tract of an animal by providing the same with β-glucan, optionally in combination with prebiotic and/or probiotic microorganisms. W097/34591 also describes the enhancement of resident population of microorganisms, or the suppression of the undesired resident population at a selected site of the GI tract of an individual, by providing the individual with a selected modified or unmodified starch or mixtures thereof, which act as carrier for one or more probiotic microorganisms and as a growth or maintenance medium for the microorganisms. The probiotic elements are bound to the carrier in a manner so as to protect the microorganisms during passage to the large bowel or other regions of the GI tract.
Microorganisms are used in a variety of industrial processes. These processes can be divided into continuous processes and batch processes. In continuous processes, such as a continuous aerobic or anaerobic fermentation line, used for the production of a variety of fermentation products, including, for example, ethanol and methanol, a fermentable raw material is continuously fed into the line and the fermentive product is continuously collected from the line, in a controlled fashion, such that the microorganism population in the line is sustained throughout the process. In batch processes, such as, but not limited to, batch aerobic or anaerobic fermentation, biodegradation of oil in, for example, oil spills, and the like, a fermentable raw material is mixed with a population of microorganism(s) so as to instate fermentation. Both in continuous fermentation and in batch fermentation processes, it is desired, in some cases, to start or reinstate the process with a large and viable population of the relevant microorganism(s). For example, when biodegrading oil, it is advantageous to start the process with an as large as possible population of the microorganisms Pseudomonas spp. or Alcaligenes spp., for example, so as to minimize the time for complete biodegradation of the oil. When using filters enriched with microorganism(s) for biodegradation of organic fumes or volatiles, the result is a continuous process in which polluting compounds are degraded into harmless compounds. However, the microorganisms present in the filter depend for their survival on continuous supply of organic fumes or volatiles. Nevertheless, in some instances the supply of organic fumes or volatiles is discontinued and, as a result, the microorganism(s) are lost. Under such circumstances, reinstation of an effective viable amount of microorganism(s) in the filter is required in a short period of time, so as permit immediate restoration of a functional filter.
There is thus a widely recognized need for, and it would be highly advantageous to have, a formulation in which microorganisms, including probiotic microorganisms and microorganisms useful in a variety of industrial applications, could be maintained viable and in a metabolically active form for long periods of time .
While reducing the present invention to practice, it has been unexpectedly found that a single species of a non-pathogenic probiotic microorganism derived from E. coli is, alone, capable of restoring normal GI flora of man and of a variety of mammals and avians. It has also been surprisingly found that this microorganism, as well as other microorganisms, could be preserved for long periods of time, in a viable and metabolically active form, in a formulation comprising water solution of volatile fraction(s) of various plant extracts. A probiotic composition comprising the probiotic organism suspended in the formulation was found to be effective in the treatment and prevention of various gastrointestinal disorders. It has further been unexpectedly found that the formulation per se is effective as a body weight gain enhancer and as an immuno-stimulator in mammals and avians.
SUMMARY OF THE INVENTION According to one aspect of the present invention there is provided an
Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799).
According to another aspect of the present invention there is provided a probiotic composition comprising viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) and a formulation for maintaining viability of the Escherichia coli strain. The probiotic composition preferably further comprising at least one flavouring agent. Preferably, the formulation includes at least one volatile fraction (VF) of a plant extract prepared by steam distillation of a plant (e.g., beet, dill, parsley or grapefruit) extract under reduced pressure and at a bath temperature preferably not exceeding 38 °C. The probiotic composition of the present invention may be identified for preventing or treating gastro-enteric infections or disorders, maintaining or reinstating normal gastro-intestinal microflora, preventing or treating diarrhea, preventing or treating gastro-enteric infection caused by an enteric pathogen, such as a Gram negative bacterium or Gram positive bacterium, preventing or treating gastro-enteric Salmonella infection, preventing or treating infectious diarrhea, caused by, for example C. difficile, Salmonella, particularly S. Shigella, Campylobacter, E. coli, Proteus,, Pseudomonas or Clostridium, chronic diarrhea or diarrhea resulting from antibiotic therapy, radiotherapy or chemotherapy, and/or for normalizing the physiological activity of the gastrointestinal tract.
According to yet another aspect of the present invention there is provided a formulation comprising at least one volatile fraction (VF) of a plant extract, the volatile fraction is prepared by steam distillation of the plant extract under reduced pressure and at a bath temperature not exceeding 38 °C. The plant extract is preferably obtainable from a plant organ selected from the group consisting of leaves, stems, roots and fruit. The plant can be a vegetable, such as soy bean, alfalfa, garlic, beet and cabbage, or a herb, such as parsley, mint and dill. The formulation may further include a beehive product, such as, but not limited to, propolis. The formulation can serve as a veterinary feed or food additive for enhancing animal weight gain in a recipient. It can also serve to preserve viable bacteria as is further described herein.
Hence, according to an additional aspect of the present invention there is provided a process of preparing a volatile fraction of a plant, comprising the steps of (a) grinding a plant derived material to give a plant biomass; (b) mixing the plant biomass with water and stirring at ambient temperature; (c) steam distilling the mixture obtained in step (b) under reduced pressure and at a bath temperature not exceeding 38°C; and (d) collecting volatile fraction obtained from the steam distillation. Preferably, the reduced pressure is of 5-10 mbar. This formulation can be used as a food additive, a feed additive and has unexpected therapeutic uses, as well as advantageous bacteria preservation properties. A therapeutic formulation containing the volatile fraction of a plant is also disclosed and may be prepared by mixing at least one volatile fraction (VF) of a plant extract with physiologically or veterinary acceptable additives, carriers or diluents. Preferably, the volatile fraction is prepared by steam distillation of the plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
Thus, according to still another aspect of the present invention there is provided a probiotic composition comprising (a) an effective amount of at least one viable probiotic microorganism having a beneficial biological or therapeutic activity in the gastrointestinal tract; and (b) at least one volatile fraction (VF) of a plant extract preferably prepared as described herein. The probiotic microorganism can be E. coli, preferably, strain BU-230-98, ATCC Deposit No. 202226 and it can be identified for treatment or prevention of any of the above disorders/pathologies/diseases/syndromes and in addition or as an alternative in can be identified for treatment or prevention of dyspeptic symptoms, for enhancing the immune response in a patient suffering from an immune disorder, resulting from, for example, immune-response suppression therapy.
According to still another aspect of the present invention there is provided a composition comprising (a) at least one microorganism, such as, Escherichia spp., Alcaligenes spp., Arthrobacter spp., Bifidobacterium spp., Lactobacillus spp., Lactococcus spp., Nitrosomonas spp. and Pseudomonas spp.; and (b) at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months, preferably at least 3-6 months, more preferably 6-12 months or more at room temperature.
According to another aspect of the present invention there is provided a process of growing Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799), the process comprising the step of seeding a starter cloture of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) into a growth media and growing the Escherichia coli strain up to optical density of 15-30 at 650 nm.
According to yet another aspect of the present invention there is provided a process of manufacturing a probiotic composition, the process comprising the step of suspending viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) in a formulation for maintaining viability of the Escherichia coli strain. Preferably, the formulation includes at least one volatile fraction (VF) of a plant extract, prepared, preferably by steam distillation of the plant extract under reduced pressure and at a bath temperature not exceeding 38 °C, obtained from, for example, a plant organ selected from the group consisting of leaves, stems, roots and fruit, either a vegetable and a herb, such as soy bean, parsley, mint, dill, alfalfa, garlic, beet or cabbage.
According to still another aspect of the present invention there is provided a process of preparing a probiotic composition, the process comprising the step of suspending an effective amount of at least one viable probiotic microorganism having a beneficial biological or therapeutic activity in the gastrointestinal tract in an formulation containing at least one volatile fraction (VF) of a plant extract. According to an additional aspect of the present invention there is provided a process of preparing a composition including viable microorganisms, the process comprising the step of suspending at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature. The microorganism can be, for example, Escherichia spp., Alcaligenes spp., Arthrobacter spp., Bifidobacterium spp., Lactobacillus spp., Lactococcus spp., Nitrosomonas spp. or Pseudomonas spp. According to yet an additional aspect of the present invention there is provided a dispenser of microorganisms comprising a reservoir and a dispensing mechanism being connected thereto, the reservoir housing at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature.
According to still an additional aspect of the present invention there is provided a method of biocontrol of an organism, the method comprising the step of spreading in an endemic area at least one viable microorganism capable of biocontrolling the organism, the at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature.
According to a further aspect of the present invention there is provided a method of eliminating an oil pollution, the method comprising the step of spreading in a polluted area at least one viable microorganism capable of degrading oil, the at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature.
According to yet a further aspect of the present invention there is provided a method of restoring organic fumes degrading microorganism population in a biofilter, the method comprising the step of dispensing onto the filter at least one viable microorganism capable of degrading organic fumes, the at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the at least one microorganism for at least 2 months at room temperature. According to still a further aspect of the present invention there is provided a method of preparing a starter for a fermentation process, the method comprising the step of growing a sufficient amount of a starter microorganism and suspending the starter microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, the at least one volatile fraction is selected so as to sustain viability of the starter microorganism for at least 2 months at room temperature.
BRIEF DESCRIPTION OF THE DRAWINGS The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice. In the drawings:
FIG. 1 is a schematic depiction of a dispenser according to the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is of (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.
The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions. Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
In one aspect, the present invention relates to a probiotic microorganism being a non-pathogenic bacterium derived from E. coli, having a beneficial physiological and/or therapeutic activity in, for example, the GI tract and deposited at the ATCC under deposit No. 202226 and at DSMZ under deposit
No. 12799.
"Probiotic" is used herein as an adjective to describe an isolated bacteria having the property of inhibiting the growth of at least one pathogen. The test of an inhibition used herein was an in vitro test on solid medium in which culture supernatants of candidate isolated bacteria were observed for their property of inhibiting the growth of a pathogen when applied to the surface of the solid medium. Typically, a paper disc impregnated with the culture supernatant of a candidate probiotic strain was placed on the surface of an agar plate seeded with the pathogen. Probiotic bacterial supernatants caused a ring of clear agar or of reduced growth density indicating inhibition of the pathogen in the vicinity of the disc. There are other tests for inhibition which are available or could be devised, including direct growth competition tests, in vitro or in vivo which can generate a panel of probiotic bacteria similar to that described herein. The bacterial strains identified by any such test are within the category of probiotic bacteria, as the term is used herein.
The probiotic bacteria of the present invention may serve as a food or feed additive, so as to provide food or feed product supplemented with viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799). A food product of the present invention may further include at least one milk derived substance and may be selected from the group consisting of a cheese and a yogurt.
The present invention further relates to a formulation comprising at least one volatile fraction (VF) of a plant extract, the volatile fraction being prepared by distillation of the plant extract under reduced pressure and at a bath temperature typically not exceeding 38 °C.
The plant matter from which the volatile fraction may be obtained may be any suitable plant part such as fruit, leaf, stem or root. Many plants are suitable as a source for the volatile fractions, for example apple, citrus, soy bean, beet, cabbage, garlic and alfalfa, as well as herbs such as parsley, mint and dill. The formulations of the invention may optionally further comprise a suitable amount of a volatile fraction of an apicultural product such as honey, propolis or other beehive product, which may be prepared in the same manner as described herein for obtaining volatile fractions from plant extracts.
As will be described in more detail in the following Examples, the formulation itself may be used as a food/feed additive. It has been found by the inventors to have a weight gain enhancing activity and it constitutes an aspect of the invention. According to a particular embodiment of this aspect of the invention, the animal weight gain enhancing formulation or feed additive comprises distilled water and volatile fractions of alfalfa, soy beans, beet and dill, preferably at a volume ratio of the volatile fractions of 2:8:1 :4. Alternatively, a formulation or feed additive of the present invention comprises distilled water and volatile fractions of carrot, beet, dill and grapefruit (1 part each) per 100 parts of water. Still alternatively, a formulation or food additive of the present invention comprises distilled water and volatile fractions of beet, dill and parsley (1 part each) per 100 parts of water. In a further aspect, the invention relates to a composition comprising the above formulation of the invention and at least one viable microorganism, either a probiotic organism having a therapeutic or beneficial biological activity in, for example, the GI tract of human and/or animal, to thereby provide a probiotic composition, or an organism having industrial applications, to thereby provide a composition of industrial applicability.
A particular advantage of the probiotic and industrial compositions of the invention stems from the fact that they are liquid preparations. Being under biologically active conditions, the formulation serves also as a supportive medium for living bacteria, as opposed to lyophilized formulations where the bacteria are in an anabiotic condition. As a result, the probiotic composition of the invention, for example, is active immediately following oral administration, beginning with the upper portion of the GI tract, where primary effects of the majority of intestinal pathogens take place, causing development of adverse gastro-enteric syndromes. The probiotic compositions of the invention may also be used as body weight-increasing preparations or food/feed additives. Similarly, the industrial composition of the invention can be used to efficiently reinstate a population of microorganisms of industrial applicability. Thus, it is noted that, for probiotic applications, probiotic bacteria other than such belonging to the strain BU-230-98 (ATCC Deposit No. 202226, also deposited at the DSM under No. 12799), may be used with the plant material derived formulation of the invention. Such probiotic bacteria have a very broad spectrum of antagonistic activity. They also belong to the same phylogenetic group of the majority of intestinal pathogens and share the same systems of survival. Therefore, the suppression and exclusion of intestinal pathogens may include many different mechanisms, for example, secretion of antagonistic material, competition for utilization of nutrients and competition for adhesion receptors. Thus, any non-pathogenic bacteria which comply with these criteria, may be used in the probiotic compositions of the invention.
According to a further aspect of the invention, the probiotic compositions of the invention may be used for preventing or treating gastro-enteric infections. Term 'gastro-enteric infection' is to be taken to mean any infection caused an enteric pathogen, including, inter alia, Gram negative and Gram positive bacteria. By improving the general balance and health of the GI tract, the formulations and probiotic compositions of the invention may be instrumental in prophylaxis of also GI infections caused by yeast, viruses and protozoa. The term 'therapeutically effective amount' or 'effective amount' for purposes herein is the amount determined by such considerations as are known in the art. The amount must be sufficient to enable the efficient restoration of the GI microflora thus leading to the normalization of the function of the GI tract. In a particular embodiment, the probiotic composition for preventing the development of gastro-enteric infections comprises the formulation of the invention made from distilled water and volatile fractions of alfalfa, soy beans, beet, dill and mint as defined herein, at a volume ratio of, e.g., 5:1:5:15:1, and a therapeutically effective amount of a probiotic bacteria such as E. coli ATCC Deposit No. 202226 (identical with DSM 12799) or any other probiotic bacteria.
A specific example for an gastro-enteric infection is that caused by Salmonella and the invention is of particular advantage in preventing or treating gastro-enteric infections caused thereby. Further, the food additive or formulation of the invention, alone or in combination with an effective amount of a probiotic microorganism, such as the E. coli strain ATCC Deposit No. 202226 (identical with DSM 12799), may be used for treating or preventing infectious diarrhea, chronic diarrhea or diarrhea caused by antibiotic or chemo-therapy.
According to a further specific embodiment of the invention, such a probiotic composition for treating diarrhea may comprise distilled water and volatile fractions of alfalfa, soy beans, beet, dill and mint at a volume ratio of, e.g., 5:1:5:15:1, and a therapeutically effective amount of the ATCC No.
202226 (DSMZ 12799).
The infectious diarrhea may be caused by numerous factors, for example, by a microorganism selected from C. difficile, Salmonella, particularly S. Shigella, Campylobacter, E. coli, Proteus, Pseudomonas, Clostridium, enteric Staphylococcus. These are but few of many infecting agents.
Yet further, the probiotic compositions of the invention may be used for effectively restoring the GI microflora in a subject in need of such treatment which leads to the normalization of the function of the GI tract. Such compositions may include, for example, distilled water and volatile fractions of alfalfa, soy bean, beet, dill, mint, parsley and cabbage, preferably at a ratio of volatile fractions of, e.g., 1 :5:5:2:2:1, and a therapeutically effective amount of the probiotic bacteria ATCC Deposit No. 202226 (DSM 12799). Other purposes for which the probiotic compositions of the invention, comprising at least one probiotic bacteria having a therapeutic effect in, for example, the GI tract, include alleviation of lactose intolerance in subjects suffering from lactose intolerance, treatment of enterocolitis, treatment of constipation, for reduction of cholesterol levels in the blood, for treatment of dyspeptic symptoms, and/or for stimulation of the immune system in subjects suffering from an immune system disorder, which may be an immune disorder caused by immuno-suppressive therapy.
In a different aspect, the invention relates to a process for preparing a volatile fraction of a plant extract, which process comprises the steps of: (a) grinding plant derived matter to obtain a plant biomass; (b) mixing the plant biomass obtained in step (a) with water at a weight proportion of preferably 3 parts water to 1 part of the plant biomass and stirring the same for at least 2 hours at ambient temperature; (c) distilling the mixture obtained in step (b) under reduced pressure and at a bath temperature preferably not exceeding 38 °C; and (d) collecting the volatile fraction obtained from the steam distillation, which fraction may further be diluted in a suitable buffer.
The volatile fraction of the invention may be mixed with water to give the food/feed additive or formulation of the invention. The food/feed additive or formulation of the invention may also be prepared by mixing more than one plant volatile fraction obtained by the process of the invention. This mixture may be further mixed with water.
The volatile fractions may be prepared from may any suitable fruit, vegetable, leaf, stem or root of a plant. The plant can be, for example, apple, citrus fruit, soy bean, beet, garlic, cabbage or alfalfa, or a herb such as parsley, mint or dill. It should be noted that when appropriate, the formulation may further comprise volatile fractions from apicultural products such as honey or propolis or other beehive products. These volatile fractions may be prepared in the same manner of the plant extract volatile fractions.
According to the process of the invention, the distillation step is preferably carried out under reduced pressure of 5-10 mbar.
As indicated hereinbefore, the food/feed additive or formulation of the invention may be further combined with at least one probiotic or industrial agent, to give the probiotic or industrial compositions of the invention. Thus, the process of preparation of the invention may also further comprise the step of suspending at least one viable probiotic or industrial microorganism in the volatile fraction obtained in said step (d) or in a mixture of such volatile fractions obtained as described above. According to a particular process of the invention, the probiotic microorganism suspended may be the novel bacterium of the invention, derived from E. coli and deposited at the ATCC under Deposit No. 202226 (and at DSM under deposit No. 12799).
Finally, the invention relates to the use of a volatile fraction (VF) of a plant extract in the preparation of a food/feed additive, wherein the VF is prepared by steam distillation of said plant extract or from apiculture product extract such as honey or propolis at a bath temperature not exceeding 38 °C.
An additional aspects of the invention include a process of preparing a composition including viable microorganisms. The process is effected by suspending at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract. The formulation is selected so as to sustain viability of the microorganism(s) for at least 2 months at room temperature. The microorganism of choice may be probiotic or have industrial applicability. Organisms which can be maintained in a formulation of the present invention include Escherichia spp., Alcaligenes spp., Arthrobacter spp., Bifidobacterium spp., Lactobacillus spp., Lactococcus spp., Nitrosomonas spp. and Pseudomonas spp. As shown in Figure 1, in another aspect the present invention provides a dispenser 10 of microorganisms. Dispenser 10 includes a reservoir 12 and a dispensing mechanism 14 connected thereto. Reservoir 12 houses at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract. The formulation is selected so as to sustain viability of the microorganism(s) for at least 2 months at room temperature. Reservoir 12 may be refrigerated, say to about 2-20 °C, preferably to about 4 °C. Dispenser 10 may be an airborne dispenser, so as to allow dispersion of pest control bioagents. The dispenser may be hand held. In any case, the dispenser may be designed to automatically dispense a predefined volume therefrom, e.g., periodically. To this end, dispenser 10 may include a programmable or preset control mechanism 16, valves 18, etc.
Thus, according to another aspect, the present invention provides a method of biocontrol of an organism which is effected by spreading in an endemic area at least one viable microorganism capable of biocontrolling the organism. The viable microorganism(s) are present in a formulation containing at least one volatile fraction (VF) of a plant extract selected so as to sustain viability of said at least one microorganism(s) for at least 2 months at room temperature. Still according to another aspect the present invention provides a method of eliminating an oil pollution which is effected by spreading in a polluted area at least one viable microorganism capable of degrading oil, such as Pseudomonas spp. The viable microorganism(s) is present in a formulation containing at least one volatile fraction (VF) of a plant extract selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
Yet according to another aspect the present invention provides a method of restoring organic fumes degrading microorganism population in a biofilter by dispensing onto the filter at least one viable microorganism, such as Pseudomonas spp., Nitrosomonas spp., or Arthrobacter spp. capable of degrading organic fumes. The viable microorganism(s) is present in a formulation containing at least one volatile fraction (VF) of a plant extract selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature. Still according to another aspect of the present invention there is provided a method of preparing a starter for a fermentation process by growing a sufficient amount of a starter microorganism, such as, Lactococcus spp., Escherichia spp., Bifidobacterium spp., Lactobacillus, Lactococcus spp. or Pseudomonas spp. and suspending the starter microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract selected so as to sustain viability of said starter microorganism for at least 2 months at room temperature.
Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
Example 1
Preparation of a "volatile fraction " of plant extracts or extracts from apiculture products Fresh vegetables obtained from commercial markets were thoroughly washed by tap water, chopped and finely ground in an industrial blender. Distilled water was added to the vegetable biomass at the proportion of 3 parts water to 1 part of the vegetable mass by weight and left under stirring for at least 2 hours at ambient temperature. The mixture was then transferred into the evaporating flask of a rotatory evaporator and was evaporated at a reduced pressure (5-10 mbar) under such conditions that the temperature of the water bath did not exceed 38 °C, and that of the condenser inlet was 2-5 °C. About 1 liter of the condensate (volatile fraction) were collected per 2.5 kg of plant biomass. This material could be preserved under refrigeration for at least 12 months without loosing its properties, as is further exemplified hereinunder.
The same procedure may be carried out, replacing the plant material with apiculture products such as honey or propolis.
Usually, each "volatile fraction" was prepared from a single kind of vegetable and used in different dilution to prepare different mixtures for various purposes. Example 2 Isolation and growth of the probiotic organism E. coli ATCC Deposit No. 202226 The probiotic organism E. coli (deposited at the ATCC under No. 202226 on May 3, 1999 and at the DSM under No. 12799 on May 4, 1999) was isolated from E. coli M-17 by sequential transfer of isolates initiating from long term (2 months) survivors preserved in a formulation containing volatile fractions of plant derived material as is described under Example 1 above at 37 °C and selecting for isolates capable of competition with pathogens as is further detailed below. The probiotic organism E. coli (deposited at the ATCC under No. 202226 on May 3, 1999 and at the DSM under No. 12799 on May 4, 1999) was grown in the following medium: (NH4)2S04 - 5 g/liter, KH2PO4 - 13 g/liter, Na2HPθ4 - 13 g/liter, MgCl2 - 3 g/liter, CaCl2 - 0.3 g/liter, yeast extract - 10 g/liter, Soy peptone - 10 g/liter and glucose - 5 g/liter. Additional nutrients (yeast extract - 1 g/liter, Soy peptone - 2.5 g/liter and glucose - 90 g/liter) were continuously added following the growth of the culture in such a way that the glucose concentration in the fermentation broth was kept at a level of 2 g/liter. The pH of the fermentation broth was kept neutral by the continuous addition of 4N NH4OH. Culturing was carried out at 30 °C in a standard fermentation vessel with aeration of 0.5 wm for 16 hours, when the growth became confluent. This procedure resulted in 10 -10 cells/ml. The E. coli cells were harvested by centrifugation, resuspended in saline and re-precipitated. The microbial biomass could be kept in saline in the refrigerator for 48 hours without loosing viability.
Example 3 Preparation of food/feed additive formulation for the accelerated increase of body weight in mammals and avians The mixture contained volatile fractions of: alfalfa - 50 ml/liter, soy beans - 200 ml/liter, beet - 25 ml/liter and dill - 100 ml/liter, prepared as described under Example 1 above. The balance was made up by the distilled water.
Example 4 Preparation of a food supplement for the normalization of the function of the human GI tract
The mixture contained volatile fractions of: alfalfa - 50 ml/liter, soy beans - 10 ml/liter, beet - 50 ml/liter, dill - 50 ml/liter, mint - 20 ml/liter, parsley - 20 ml/liter and cabbage - 10 ml/liter, prepared as described under Example 1 above. The balance was made up by distilled water. E. coli (ATCC 202226) cells (Example 2) were suspended in the mixture at a cell ηη ccoonncceennttrraatitioonn ooff 1100 cceellllss//mmll.. N NaCl (e.g., 4-10 g/liter) may be optionally added for the improvement of taste.
Example 5
Preparation of a feed additive formulation for the prophylaxis of GI infections in mammals and avians The mixture contained volatile fractions of: alfalfa - 50 - ml/liter, soy beans - 10 ml/liter, beet - 50 ml/liter, dill - 150 ml/liter and mint - 10 ml/liter, prepared as described under Example 1 above. The balance was made by distilled water. E. coli (ATCC 202226) cells (Example 2) were suspended in η tthhee mmiixxttuurree aatt aa cceellll ccoonncceennttrraattiioonn ooff 1100 cceellllss//mml. NaCl (4-10 g/liter) may be optionally added for the improvement of the taste
Example 6
Antagonistic activity ofE. coli (ATCC 202226) against
Salmonella typhymirium (ATCC 14028) Petri plates containing Modified Brilliant Green Agar, a selective growth medium for Salmonella, were inoculated with S. typhimirium. A 9 mm diameter well was made in the agar. A volume of the food supplement (Example 4) was deposited in each well, and the plates were incubated for 24 hours at 35 °C. The same was repeated, but instead of the food supplement, the fluid obtained by its filtration through a microbiological filter membrane (pore size of 0.45 μm) was deposited in the well.
Around each well containing the feed additive an inhibition zone (10-17 mm) devoid of S. typhimirium colonies was observed. No inhibition zone was observed around the wells containing the filtrate free of the probiotic organism.
Example 7
Antagonistic activity ofE. coli ATCC 202226 as well as of its parent strain E. coli M-l 7 against Shigella sps. Cultures of S. flexneri, S. sonnei, E. coli (ATCC 202226) and M-l 7 were grown separately on a Nutrient Agar for 18-20 hours at 37 °C. All the cultures were harvested in saline and diluted to an optical density of 10 Klett units. Aliquots of the diluted cultures of Shigella species (1 ml) alone or in combination with the diluted culture of E. coli (ATCC 202226) (1 ml) were seeded in ventilation-cup test tubes containing Nutrient Broth (5 ml). The tubes were incubated for 24 hours at 37 °C. The number of colony-forming units (CFU) of the pathogens and of E. coli (ATCC 202226) was determined by plating the cultures on Nutrient agar. The CFU numbers of two Shigella species in the pure culture and in mixed cultures with both probiotic E. coli species are shown in Table 1 below.
Table 1
Figure imgf000019_0001
Example 8
Application of the food supplement (Example 4) and of Colibacterin (dry formulation ofE. coli M-l 7) in hospitalized gastroenteritis patients A group of 60 patients that developed gastroenteritis following hospitalization was randomly divided into 3 sub-groups with a similar distribution of sex, age and the severeness of gasroenteritis symptoms. All patients received normal supportive treatment, including rehydration, vitamins, etc. The severity of condition did not require treatment with antibiotics. The first group of 20 patients received 10 ml of the food supplement (Example 5) 3 times daily 30 minutes before the meals for 7 days. The second group of the same number received Colibacterin (Colibacterinum siccum) as recommended by the producer (one dose twice a day 30 minutes before the meal) and the third group received no supplement at all. The onset of normalization (in days) of the symptoms of gastroenteritis in all groups were recorded and are shown in Table 2 below.
Table 2
Figure imgf000019_0002
Figure imgf000020_0001
Table 2 (Continued)
Colibacterin (Colibacterinum siccum) is the freeze-dried preparation of live E. coli M-l 7 produced by BIOMED Ltd., Moscow, Russia, and recommended for use against diarrhea [Vidal Handbook: Pharmaceutical preparations in Russia (N.B. Nikolaeva, B.P. Alperovich and V.N. Sovinov, Eds.) AstraPharmService, 1997, Moscow, p. 275].
Example 9
Application of the food supplement (Example 4) in patients with acute GI infections
Patients with severe GI infections of various etiologies: salmonellosis, escherichiosis, shigellosis, staphylococcal infections and food intoxications of unknown etiology were included in the study. In all patients the hospitalization was indicated by an acute onset of the disease and appearance of acute gastroenteritis. The total of 186 patients were treated with the food supplement and a similar group of 102 patients received standard treatment.
The onset of normalization (in days) of the symptoms of gastroenteritis in all groups were recorded and are shown in Table 3 below.
Table 3
Figure imgf000020_0002
In a separate study a group of 30 patients with intestinal typhoid was treated with the food supplement. In 80 % of patients the symptoms of disease disappeared within 3 days. Only in 3 cases the supplement treatment was stopped due to the development of more severe chronic colitis. Example 10
Applications of the food supplement (Example 4) in patients with GI disorders caused by antibiotics
Patients with severe GI disorders were divided in 2 groups. Group I contained 48 patients with peptic ulcer disease who developed GI disorders after antibiotic treatment against H. pylori. Group II contained 22 patients that developed GI disorders following antibiotic treatment of pneumonia.
The food supplement (5 ml) was given 3 times a day before meals for 7 days. In both groups symptoms of diarrhea disappeared in 2-3 days in all the patients. After the administration of the supplement, complete normalization of intestinal microflora was observed in 84.5 % of the patients. It was demonstrated by a dramatic increase in lactobacilli and Bifidobacteria, reduction on the general count of E. coli, complete disappearance of the hemolytic E. coli and other pathogens such as Staphylococci, Proteus vulgaris and even Candida sps. In the remaining 15.5 % of the patients, a significant improvement was observed.
Example 11 Application of the food supplement (Example 5) in patients with late radiation enterocolitis
The food supplement (10 ml, 3 times a day for 14 days, 30 minutes before the meals) was given to 24 patients with womb, colon and gastric cancer that developed enterocolitis following radiation therapy or a combination of radiation and chemotherapy. Prior to the use of the food supplement, all patients complained about frequent and painful desire to defecate, liquid stool (4-12 times a day) appearance of mucous (9 cases) and blood (3 cases) in the stool.
Two or three days after ingesting the supplement, all the patients noted the lessening of pain and reduction in the number of defecations; the stool had a normal appearance. Four to five days later the diarrheal syndrome was gone, the appearance of blood and mucus ceased. The blood analysis showed a strong improvement in blood indicators.
In the control group of a similar size the symptoms persisted.
Example 12
Application of the food supplement (Example 4) in AIDS patients
Patients suffering from AIDS frequently develop chronic diarrhea. A group of such patients was given 10 ml of the food supplement (Example 5) 3 times a day 30 minutes before the meals for 20 days. The control group received no supplement. The results of the treatment are shown in Table 4 below.
Table 4
Figure imgf000022_0001
Patients receiving the food supplement showed normalization of intestinal microflora: reduction in general number of coliforms, disappearance of the hemoiytic E. coli, increase in the numbers of Lactobacilli and Bifidobacteria, reduction in Candida sps.
Example 13 Application of the food/feed additive (Example 3) for accelerated weight increase in healthy piglets Healthy piglets were administrated 3 ml per os of the food/feed additive per piglet per day until weaning. The group receiving the feed additive gained weight at weaning on the average 1.0 kg per piglet more than the control group.
Example 14
Application of the feed additive (Example 5) in healthy piglets
Several hundreds healthy piglets were administrated 3 ml per os of the feed additive per piglet on the first and third day after delivery and at weaning. Mortality was cut down by 50 % compared with the control group receiving standard prophylactic treatment with antibiotics. The group receiving the feed additive gained weight at weaning on the average 0.39 kg per piglet more than the control group. When the feed additive and antibiotic treatment were compared in the same litter, the weight gain in the piglets obtaining the feed additive was found higher by 2.4 kg than in the control. Example 15
Application of the feed additive (Example 4) in piglets showing diarrhea
Several hundred piglets showing diarrhea were given daily 5 ml per os of the feed additive per piglet. The control group of the same size was treated with antibiotics: advocin, gentiamycin, amoxicillin. The symptoms of diarrhea in the group receiving the feed additive disappeared within 1-2 days. No mortality was observed, and piglets developed normally. Antibiotics stopped diarrhea in the great majority of piglets but the piglets remained stunted in their development. About 70 retarded piglets, that received antibiotic treatment against diarrhea for a week, and generally considered lost, were given the feed additive for three days. All but two survived.
Example 16 Application of the feed additive (Example 4) in healthy calves
Day-old healthy calves were administrated 5 ml of the feed additive a day in milk during 7 days. More than 95 % of the calves did not developed diarrhea until they were 14 days old, when a few cases positive for Rotavirus were diagnosed. Normally, the incidence of diarrhea in this farm is 20-30 %.
Example 17 Application of the feed additive (Example 6) in calves showing diarrhea Calves developing diarrhea were given daily 10 ml of the feed additive per animal with milk during 3-5 days. The symptoms of diarrhea disappeared within 1-2 days in 90-95 % of calves. In the remaining 5-10 % the diarrhea was caused by virus. These calves were treated with antibiotics with poor results.
Example 18 Application of the feed additive (Example 6) in healthy lambs and goat kids
Day-old healthy lambs and goat kids were administrated 3 ml of the feed additive a day in milk during 7 days. In some cases slight to moderate signs of diarrhea were observed. These signs usually disappeared spontaneously or were successfully treated with an increased dose of the feed additive (5 ml). Normally the insidence of diarrhea in these farms is 50 % for baby lambs and for goat kids. Example 19
Application of the feed additive (Example 5) in lambs and goat kids showing diarrhea
The feed additive was tested in a herd suffering from pathogenic E. coli infections. In the year preceding the experiment, about 90 from 120 lambs and goat kids died from diarrhea. Treatment with antibiotics was ineffective, since the disease developed suddenly and with fast mortality. Lambs and goat kids developing diarrhea were given daily 5 ml of the feed additive per animal with milk during 3-5 days. A matching group of animals was treated, as normally recommended, with antibiotics. The symptoms of diarrhea disappeared within 1-2 days in about 90 % of the lambs and goat kids receiving the feed additive. Their further development appeared normal. The control group receiving antibiotics (gentamycin) showed much poorer results. Diarrhea in this group persisted, calling for repeated treatment with antibiotics. The development of the control group was severely retarded.
Example 20 Application of the feed additive (Example 5) in poultry
The feed additive was added to the drinking water with the average uptake of 0.01 ml of the additive per day per chick during the breeding period (42-49 days). An increase of 3.2 % in weight gain, accompanied by 4 % improvement in food conversion was noted in controlled trials in broilers.
Excellent results were also obtained with turkeys of age 1 day to 6 weeks. Each bird received 0.01 ml of the additive per day. A weight gain of over 10 % was observed, along with reduced mortality rate. Birds which still exhibited diarrhea, were treated with 0.1 ml per day of the food additive, without any treatment by antibiotics, and showed better recovery from the control birds which were treated with only antibiotics.
Example 21
Application of the feed additive (Example 5) in dogs and cats
Application of the feed additives in puppies resulted in cessation of the symptoms of diarrhea within 24-48 hours. Example 22
Application of the feed additive (Example 5) in mice;
Evidence for immunostimulation
Two-weeks-old C571B1 mice were divided into 4 groups of 10 animals in each. Mice were deprived water from 4:00 pm to 8:00 am and then given 15 ml of either water (groups 1 & 3) or the feed additive (groups 2 & 4). This treatment was repeated for 2 weeks. At the end of this treatment mice from groups 3 and 4 were subjected to laparotomy under ether narcosis. A cut of 1.5 cm was made in the abdominal wall. Irritation of intestine was carried out by a dry gause. All the mice were sacrificed 24 hours after laparatomy; spleens were excised. Splenocytes were isolated and cultured on RPMI medium for 48-72 hours in the presence of phytohemagglutinin (PHA). In the group treated with the feed additive the proliferative activity of splenocytes reduced by laparotomy was recovered. Splenocytes proliferation induced by PHA:
1. Control group/water 3060±290
2. Control group/water/laparotomy 2120±300
3. Test group/BioCocktail 2740±370
4. Test group/BioCocktail/laparotomy 3040±520
Example 23 Application of the food additive (Example 4) in human; Evidence for immunostimulation A number of patients were operated for malignant tumors of womb, cervix, stomach, and intestine. The gynecological patients (20 patients) received follow-up radiotherapy; the abdominal patients (30 patients) received chemotherapy. About half of the patients received the food additive twice daily for the duration of therapy. In all patients receiving the food additive there was observed a significant immunostimulation, as expressed in:
Gynecological tumors Abdominal tumors
Control Food Additive Control Food Additive
T-lymphocytes O.G3±0.01 0.10±0.03 l.O±O.l 1.6--0.2
(CD3+, HLA-, DR+) Lymphocyte blast transformation a. spontaneous 530±110 880±80 700±120 1070±100 b. PHA-induced 16G0±360 572G±2100 4400±1340 13370±3720
Phagocytes No. (%) 60.7±2.9 76.5±2.2 57.7±1.5 74.2±1.9
Example 24 Bacteria preservation effect of the formulation
E. coli cells were dispersed in a formulation prepared as described under Example 1 above and was maintained for 6 months at room temperature. Both at the beginning and at the end of the 6 months period,, samples derived from the dispersion were seeded at appropriate consecutive dilutions on nutrient broth agar plates. The number of colony forming units was determined for both samples. The concentration determined was lxlO7 in both cases, showing the effect of the formulation in preserving microorganisms. The above experiment was performed in parallel with Pseudomonas putida, yielding the same results.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference.
In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

Claims

WHAT IS CLAIMED IS:
1. Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799).
2. A probiotic composition comprising viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) and a formulation for maintaining viability of said Escherichia coli strain.
3. The probiotic composition of claim 2, further comprising at least one flavouring agent.
4. The probiotic composition of claim 2, wherein said formulation includes at least one volatile fraction (VF) of a plant extract.
5. The probiotic composition of claim 4, wherein said volatile fraction is prepared by steam distillation of said plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
6. The probiotic composition of claim 4, wherein said plant extract is obtained from a plant organ selected from the group consisting of leaves, stems, roots and fruit.
7. The probiotic composition of claim 4, wherein said plant extract is obtained from a plant selected from the group consisting of a vegetable and a herb.
8. The probiotic composition of claim 7, wherein said vegetable is selected from the group consisting of soy bean, alfalfa, garlic, beet and cabbage.
9. The probiotic composition of claim 7, wherein said herb is selected from the group consisting of parsley, mint and dill.
10. The probiotic composition of claim 4, further comprising a beehive product.
11. The probiotic composition of claim 10, wherein said beehive product is propolis.
12. The probiotic composition of claim 2, identified for preventing or treating gastro-enteric infections or disorders.
13. The probiotic composition of claim 2, identified for maintaining or reinstating normal gastro-intestinal microflora.
14. The probiotic composition of claim 2, identified for preventing or treating diarrhea.
15. The probiotic composition of claim 14, identified for the prevention or treatment of gastro-enteric infection caused by an enteric pathogen.
16. The probiotic composition of claim 15, wherein said pathogen is a Gram negative bacterium or Gram positive bacterium.
17. The probiotic composition of claim 2, comprising distilled water and volatile fractions of beet, dill and parsley.
18. The probiotic composition of claim 2, comprising distilled water and volatile fractions of beet, dill and grapefruit.
19. The probiotic composition of claim 2, identified for preventing or treating gastro-enteric Salmonella infection.
20. The probiotic composition of claim 2, identified for preventing or treating infectious diarrhea, chronic diarrhea or diarrhea resulting from antibiotic therapy, radiotherapy or chemotherapy.
21. The probiotic composition of claim 2, identified for treating infectious diarrhea, comprising distilled water and volatile fractions of beet, dill and parsley.
22. The probiotic composition of claim 21, wherein said infectious diarrhea is caused by C. difficile, Salmonella, particularly S. Shigella, Campylobacter, E. coli, Proteus,, Pseudomonas or Clostridium.
23. The composition of claim 2, identified for normalizing the physiological activity of the gastrointestinal tract.
24. A formulation comprising at least one volatile fraction (VF) of a plant extract, said volatile fraction being prepared by steam distillation of said plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
25. The formulation of claim 24, wherein said plant extract is obtained from a plant organ selected from the group consisting of leaves, stems, roots and fruit.
26. The formulation of claim 24, wherein said plant extract is obtained from a plant selected from the group consisting of a vegetable and a herb.
27. The formulation of claim 26, wherein said vegetable is selected from the group consisting of soy bean, alfalfa, garlic, beet and cabbage.
28. The formulation of claim 26, wherein said herb is selected from the group consisting of parsley, mint and dill.
29. The formulation of claim 24, further comprising a beehive product.
30. The formulation of claim 29, wherein said beehive product is propolis.
31. A veterinary feed additive for enhancing animal weight gain comprising at least one volatile fraction (VF) of a plant extract, said volatile fraction being prepared by steam distillation of said plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
32. The veterinary feed additive of claim 31, comprising distilled water and volatile fractions of beet, dill and grapefruit.
33. A food additive for enhancing weight gain in a recipient thereof, the food additive comprising at least one volatile fraction (VF) of a plant extract, said volatile fraction being prepared by steam distillation of said plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
34. The food additive of claim 33, comprising distilled water and volatile fractions of beet, dill and parsley.
35. A probiotic composition comprising:
(a) an effective amount of at least one viable probiotic microorganism having a beneficial biological or therapeutic activity in the gastrointestinal tract; and
(b) at least one volatile fraction (VF) of a plant extract.
36. The probiotic composition of claim 35, further comprising at least one flavouring agent.
37. The probiotic composition of claim 35, wherein said volatile fraction being prepared by steam distillation of said plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
38. The probiotic composition of claim 35, wherein said probiotic microorganism is E. coli.
39. The probiotic composition of claim 37, wherein said probiotic microorganism is the E. coli strain BU-230-98, ATCC Deposit No. 202226.
40. The probiotic composition of claim 35, identified for preventing or treating gastro-enteric infections or disorders.
41. The probiotic composition of claim 35, identified for maintaining or reinstating normal gastrointestinal microflora.
42. The probiotic composition of claim 35, identified for preventing or treating diarrhea.
43. The probiotic composition of claim 35, identified for the prevention or treatment of gastro-enteric infection caused by an enteric pathogen.
44. The probiotic composition of claim 43, wherein said pathogen is a Gram negative bacterium or Gram positive bacterium.
45. The probiotic composition of claim 43, for treating dyspeptic symptoms.
46. The probiotic composition of claim 43, for enhancing the immune response in a patient suffering from an immune disorder.
47. The probiotic composition of claim 46, wherein said immune disorder results from immune-response suppression therapy.
48. The probiotic composition of claim 35, comprising distilled water and volatile fractions of beet and dill.
49. The probiotic composition of claim 35, identified for preventing or treating gastro-enteric Salmonella infection.
50. The probiotic composition of claim 35, identified for preventing or treating infectious diarrhea, chronic diarrhea or diarrhea resulting from antibiotic therapy, radiotherapy or chemotherapy.
51. The probiotic composition of claim 35, identified for treating infectious diarrhea, comprising distilled water and volatile fractions of beet and dill.
52. The probiotic composition of claim 51, wherein said infectious diarrhea is caused by C. difficile, Salmonella, particularly S. Shigella, Campylobacter, E. coli, Proteus,, Pseudomonas or Clostridium.
53. The composition of claim 35, identified for normalizing the physiological activity of the gastrointestinal tract.
54. The probiotic composition of claim 53, comprising distilled water and wherein said volatile fractions are of alfalfa, soy beans, beet, dill, mint, parsley and cabbage and said probiotic microorganism is E. coli strain BU-230-98, ATTC Deposit No. 202226.
55. A composition comprising:
(a) at least one microorganism; and
(b) at least one volatile fraction (VF) of a plant extract, said at least one volatile fraction is selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
56. The composition of claim 55, wherein said at least one microorganism is selected from the group consisting of Escherichia spp., Alcaligenes spp., Arthrobacter spp., Bifidobacterium spp., Lactobacillus spp., Lactococcus spp., Nitrosomonas spp. and Pseudomonas spp.
57. A process of preparing a volatile fraction of a plant, comprising the steps of:
(a) grinding a plant derived material to give a plant biomass;
(b) mixing said plant biomass with water and stirring at ambient temperature;
(c) steam distilling the mixture obtained in step (b) under reduced pressure and at a bath temperature not exceeding 38°C; and
(d) collecting volatile fraction obtained from said steam distillation.
58. The process of claim 57, wherein said plant extract is obtained from the leaves, stems, roots or fruit of a plant.
59. The process of claim 58, wherein said plant is a vegetable or herb.
60. The process of claim 59, wherein said vegetable or herb is selected from the group consisting of soy, alfalfa, garlic, beet, dill, mint parsley, grapefruit and cabbage. .
61. The process of claim 57, wherein said reduced pressure is of 5-10 mbar.
62. A process of preparing a therapeutic formulation, comprising the step of mixing at least one volatile fraction (VF) of a plant extract with physiologically or veterinary acceptable additives, carriers or diluents.
63. The process of claim 62, wherein said volatile fraction is prepared by steam distillation of said plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
64. A process of growing Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799), the process comprising the step of seeding a starter cloture of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) into a growth media and growing said Escherichia coli strain up to optical density of 15-30 at 650 nm.
65. A process of manufacturing a probiotic composition, the process comprising the step of suspending viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) in a formulation for maintaining viability of said Escherichia coli strain.
66. The process of claim 65, wherein said formulation includes at least one volatile fraction (VF) of a plant extract.
67. The process of claim 66, wherein said volatile fraction is prepared by steam distillation of said plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
68. The process of claim 66, wherein said plant extract is obtained from a plant organ selected from the group consisting of leaves, stems, roots and fruit.
69. The process of claim 66, wherein said plant extract is obtained from a plant selected from the group consisting of a vegetable and a herb.
70. The process of claim 69, wherein said vegetable or herb is selected from the group consisting of soy bean, parsley, mint, dill, alfalfa, garlic, beet and cabbage.
71. The process of claim 66, further comprising the addition of a beehive product.
72. The process of claim 71, wherein said beehive product is propolis.
73. The process of claim 65, wherein said at least one volatile fraction is of alfalfa, soy beans, beet, dill and mint.
74. A process of preparing a probiotic composition, the process comprising the step of suspending an effective amount of at least one viable probiotic microorganism having a beneficial biological or therapeutic activity in the gastrointestinal tract in an formulation containing at least one volatile fraction (VF) of a plant extract.
75. The process of claim 74, wherein said volatile fraction is prepared by steam distillation of said plant extract under reduced pressure and at a bath temperature not exceeding 38 °C.
76. The process of claim 74, wherein said probiotic microorganism is E. coli.
77. The process of claim 75, wherein said probiotic microorganism is the E. coli strain BU-230-98, ATCC Deposit No. 202226.
78. The process of claim 74, wherein said at least one volatile fraction includes volatile fractions of alfalfa, soy beans, beet, dill, mint, parsley and cabbage.
79. A process of preparing a composition including viable microorganisms, the process comprising the step of suspending at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, said at least one volatile fraction is selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
80. The process of claim 79, wherein said at least one microorganism is selected from the group consisting of Escherichia spp., Alcaligenes spp., Arthrobacter spp., Bifidobacterium spp., Lactobacillus spp., Lactococcus spp., Nitrosomonas spp. and Pseudomonas spp. .
81. A dispenser of microorganisms comprising a reservoir and a dispensing mechanism being connected thereto, said reservoir housing at least one microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, said at least one volatile fraction is selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
82. The dispenser of claim 81 , wherein said dispenser is airborne.
83. The dispenser of claim 81 , wherein said dispenser is hand held.
84. The dispenser of claim 81, wherein said dispenser is designed to automatically dispense a predefined volume.
85. The dispenser of claim 81, wherein said dispenser is designed to automatically dispense said predefined volume periodically.
86. A method of biocontrol of an organism, the method comprising the step of spreading in an endemic area at least one viable microorganism capable of biocontrolling the organism, said at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, said at least one volatile fraction is selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
87. A method of eliminating an oil pollution, the method comprising the step of spreading in a polluted area at least one viable microorganism capable of degrading oil, said at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, said at least one volatile fraction is selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
88. A method of restoring organic fumes degrading microorganism population in a biofilter, the method comprising the step of dispensing onto the filter at least one viable microorganism capable of degrading organic fumes, said at least one viable microorganism being in a formulation containing at least one volatile fraction (VF) of a plant extract, said at least one volatile fraction is selected so as to sustain viability of said at least one microorganism for at least 2 months at room temperature.
89. A food product supplemented with viable Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799).
90. The food product of claim 89, comprising at least one milk derived substance.
91. The food product of claim 90, selected from the group consisting of a cheese and a yogurt.
92. A method of preparing a starter for a fermentation process, the method comprising the step of growing a sufficient amount of a starter microorganism and suspending said starter microorganism in a formulation containing at least one volatile fraction (VF) of a plant extract, said at least one volatile fraction is selected so as to sustain viability of said starter microorganism for at least 2 months at room temperature.
PCT/IL2001/001088 1999-06-03 2001-11-27 Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof WO2002043649A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MXPA03004851A MXPA03004851A (en) 2000-11-30 2001-11-27 Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof.
EP01998302A EP1343370A4 (en) 2000-11-30 2001-11-27 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
KR10-2003-7007337A KR20030082549A (en) 2000-11-30 2001-11-27 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
AU2100402A AU2100402A (en) 2000-11-30 2001-11-27 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
IL15621301A IL156213A0 (en) 2000-11-30 2001-11-27 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
NZ526748A NZ526748A (en) 2000-11-30 2001-11-27 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
JP2002545628A JP4410992B2 (en) 2000-11-30 2001-11-27 Bacterial strains, treated plant extracts, compositions containing them, methods for their preparation, and their therapeutic and industrial applications
AU2002221004A AU2002221004B2 (en) 2000-11-30 2001-11-27 Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
BR0116178-4A BR0116178A (en) 2000-11-30 2001-11-27 Bacterial strain, probiotic composition comprising a bacterial strain, formulation comprising at least a volatile fraction of a plant extract, food additive, process for preparing a volatile fraction of a plant, process for preparing a therapeutic formulation, process for growing a bacterial strain, process for manufacturing a probiotic composition, process for preparing a probiotic composition, process for preparing a composition including viable microorganisms, microorganism dispenser, method of biocontrolling an organism, method for eliminating an oil pollution, method recovery of organic fumes, food product and initial preparation method for a fermentation process
CA002430292A CA2430292A1 (en) 2000-11-30 2001-11-27 Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
US10/432,346 US7504251B2 (en) 1999-06-03 2001-11-27 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
AU2007201690A AU2007201690A1 (en) 2000-06-01 2007-04-17 Preparation of Compositions Comprising Bacterial Strains and Volatile Plant Extracts and Therapeutic and Industrial Applications Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/725,846 US6500423B2 (en) 1999-06-03 2000-11-30 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
US09/725,846 2000-11-30

Publications (3)

Publication Number Publication Date
WO2002043649A2 true WO2002043649A2 (en) 2002-06-06
WO2002043649A3 WO2002043649A3 (en) 2002-08-29
WO2002043649A8 WO2002043649A8 (en) 2004-04-29

Family

ID=24916190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/001088 WO2002043649A2 (en) 1999-06-03 2001-11-27 Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof

Country Status (14)

Country Link
EP (1) EP1343370A4 (en)
JP (1) JP4410992B2 (en)
KR (1) KR20030082549A (en)
CN (1) CN1294253C (en)
AU (2) AU2002221004B2 (en)
BR (1) BR0116178A (en)
CA (1) CA2430292A1 (en)
IL (1) IL156213A0 (en)
MX (1) MXPA03004851A (en)
NZ (1) NZ526748A (en)
PL (1) PL366363A1 (en)
RU (1) RU2281326C2 (en)
WO (1) WO2002043649A2 (en)
ZA (1) ZA200304747B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105596A1 (en) * 2002-06-06 2003-12-24 Mars, Incorporated Mammalian animal compositon
WO2005017095A2 (en) * 2003-08-18 2005-02-24 The Bio Balance Corporation A stable liquid probiotic composition, preparation and applications thereof
US7018629B2 (en) 2002-10-06 2006-03-28 The Bio Balance Corporation Probiotic compositions for the treatment of inflammatory bowel disease
WO2007136719A2 (en) * 2006-05-18 2007-11-29 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
EP2463382A1 (en) 2010-12-07 2012-06-13 Enterologics, Inc. Method for identifying E. Coli M-17
US8399238B2 (en) 2004-03-24 2013-03-19 Nestec S.A. Shelf-stable product with living micro-organisms
KR20150036698A (en) * 2012-07-20 2015-04-07 프레브테크 마이크로비아 인코포레이티드 Non-Pathogenic F18 E. Coli Strain and Use Thereof
EP2953472A4 (en) * 2012-11-23 2017-03-01 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9855303B2 (en) 2013-02-04 2018-01-02 Seres Therapeutics, Inc. Compositions and methods
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10265350B2 (en) 2012-09-25 2019-04-23 Universidad De Leon Probiotic and prebiotic compositions
CN110004072A (en) * 2018-11-12 2019-07-12 西安交通大学 One plant of probiotic enterococcus faecalis separation strains A3-1 and its application
US10864235B2 (en) 2012-11-23 2020-12-15 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10881696B2 (en) 2013-03-15 2021-01-05 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US11058681B2 (en) 2013-03-14 2021-07-13 Maregade RX Product and method for treating diarrhea
CN113652340A (en) * 2021-08-24 2021-11-16 江苏江大源生态生物科技股份有限公司 Probiotic preparation, strain screening device and screening method
US11419868B2 (en) 2016-12-23 2022-08-23 White Sands Pharma Llc Low dose product and method for treating diarrhea
RU2785174C1 (en) * 2022-02-18 2022-12-05 Федеральное государственное бюджетное учреждение науки Пермский федеральный исследовательский центр Уральского отделения Российской академии наук (ПФИЦ УрО РАН) Probiotic for the prevention and correction of gastrointestinal diseases of farm animals and poultry
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453320C2 (en) * 2008-08-05 2012-06-20 Виктор Владимирович Чалов Oral composition containing nonpathogenic microorganisms showing ability to normalise intestinal microflora (versions)
KR101127171B1 (en) * 2009-07-24 2012-03-20 (주)애드바이오텍 Composition of feed additives for ducks comprising egg yolk containing IgY against pathogen to induce acute and chronic infection disease
RU2458527C1 (en) * 2010-12-30 2012-08-20 Общество с ограниченной ответственностью "БИОТРОФ" Method for production of preparation for feeding farm animals and birds and method for preparation of fodder based on it
RU2660355C2 (en) * 2016-04-01 2018-07-05 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Antibacterial pharmaceutical composition for oral use containing bacteriophages
BR112018075853A2 (en) * 2016-06-14 2019-03-19 Prevtec Microbia Inc. animal feed including an animal feed additive, method of production and use thereof.
RU2639544C1 (en) * 2016-12-16 2017-12-21 Общество с ограниченной ответственностью "БИОРЕАКТОР" Means for treatment and prevention of bird gastrointestinal tract diseases
CN107319103A (en) * 2017-08-01 2017-11-07 河南牧业经济学院 Promote feed addictive of growth of animals or poultry and intestinal growth and its preparation method and application
KR101939080B1 (en) * 2017-10-23 2019-01-16 고려대학교 산학협력단 Pseudomonas veronii strain KACC 81051BP and composition for comprising the same
CN109260235A (en) * 2018-10-23 2019-01-25 上海市第十人民医院 A kind of application of composition in preparation prevention and treatment constipation drug or health care product
CN113616715B (en) * 2021-08-31 2022-05-06 昆明理工大学 Fermented traditional Chinese medicine oral liquid for treating piglet diarrhea and improving intestinal flora thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908028A (en) * 1973-04-19 1975-09-23 Procter & Gamble Soft drink composition containing paramethoxycinnamaldehyde as a flavoring agent and sweetner
US4986985A (en) * 1987-11-02 1991-01-22 Bar Ilan University Method of treating skin virus infections
US5082489A (en) * 1990-02-06 1992-01-21 The Royal Institution For The Advancement Of Learning (Mcgill University) Composition for biocontrol of wild buckwheat
US5176913A (en) * 1988-06-24 1993-01-05 Emil Flachsmann Ag Process for preparing a partial extract containing the volatile in steam components and further lipophilic components of medical plants and/or spice plants
US5376374A (en) * 1993-05-24 1994-12-27 Zelaya; Luz M. Oral rinse composition
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5478557A (en) * 1992-07-29 1995-12-26 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
US5486367A (en) * 1992-10-13 1996-01-23 Kansas State University Research Foundation Enzymatic method for accelerating fermentation of comestible products
US5679364A (en) * 1995-06-07 1997-10-21 Lee County Mosquito Control District Compositions and methods for reducing the amount of contaminants in aquatic and terrestrial environments
US5733774A (en) * 1995-02-02 1998-03-31 Ecoscience Corporation Method and composition for producing stable bacteria and bacterial formulations
US5801052A (en) * 1995-07-29 1998-09-01 Siemens Plc Aqueous sample testing apparatus
US5876773A (en) * 1995-05-12 1999-03-02 Hagiwara; Yoshihide Process of making a plant extract
US5888395A (en) * 1996-08-30 1999-03-30 The Regents Of The University Of California Method for enhanced longevity of in situ microbial filter used for bioremediation
US6013304A (en) * 1996-12-13 2000-01-11 Kalamazoo Holdings, Inc. High temperature countercurrent solvent extraction of herb or spice solids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1501098A (en) * 1974-06-11 1978-02-15 Brewing Patents Ltd Preparation of hop oil
CA2222563C (en) * 1995-05-26 2012-01-10 Ropapharm B.V. Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and veterinary medical field
US5965128A (en) * 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
IL130303A0 (en) * 1999-06-03 2000-06-01 M G Novobiotech Ltd A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908028A (en) * 1973-04-19 1975-09-23 Procter & Gamble Soft drink composition containing paramethoxycinnamaldehyde as a flavoring agent and sweetner
US4986985A (en) * 1987-11-02 1991-01-22 Bar Ilan University Method of treating skin virus infections
US5176913A (en) * 1988-06-24 1993-01-05 Emil Flachsmann Ag Process for preparing a partial extract containing the volatile in steam components and further lipophilic components of medical plants and/or spice plants
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5082489A (en) * 1990-02-06 1992-01-21 The Royal Institution For The Advancement Of Learning (Mcgill University) Composition for biocontrol of wild buckwheat
US5478557A (en) * 1992-07-29 1995-12-26 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
US5486367A (en) * 1992-10-13 1996-01-23 Kansas State University Research Foundation Enzymatic method for accelerating fermentation of comestible products
US5376374A (en) * 1993-05-24 1994-12-27 Zelaya; Luz M. Oral rinse composition
US5733774A (en) * 1995-02-02 1998-03-31 Ecoscience Corporation Method and composition for producing stable bacteria and bacterial formulations
US5876773A (en) * 1995-05-12 1999-03-02 Hagiwara; Yoshihide Process of making a plant extract
US5679364A (en) * 1995-06-07 1997-10-21 Lee County Mosquito Control District Compositions and methods for reducing the amount of contaminants in aquatic and terrestrial environments
US5801052A (en) * 1995-07-29 1998-09-01 Siemens Plc Aqueous sample testing apparatus
US5888395A (en) * 1996-08-30 1999-03-30 The Regents Of The University Of California Method for enhanced longevity of in situ microbial filter used for bioremediation
US6013304A (en) * 1996-12-13 2000-01-11 Kalamazoo Holdings, Inc. High temperature countercurrent solvent extraction of herb or spice solids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRUENWALD ET AL. PDR FOR HERBAL MEDICINES 1998, MEDICAL ECONOMICS COMPANY, INC. (MONTVALE, NJ), page 699, 646 - 647, 890, 1022 - 1025, XP002950144 *
MURRAY ET AL. MANUAL OF CLINICAL MICROBIOLOGY (SIXTH EDITION) 1996, AMERICAN SOCIETY FOR MICROBIOLOGY PRESS (WASHINGTON, DC), page 79, XP002950146 *
See also references of EP1343370A2 *
SINGLETON ET AL. DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY 1991, JOHN WILEY AND SONS (NEW YORK), page 917, XP002950145 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427398B2 (en) 2002-06-06 2008-09-23 Mars, Inc. Mammalian animal composition
WO2003105596A1 (en) * 2002-06-06 2003-12-24 Mars, Incorporated Mammalian animal compositon
US7018629B2 (en) 2002-10-06 2006-03-28 The Bio Balance Corporation Probiotic compositions for the treatment of inflammatory bowel disease
WO2005017095A2 (en) * 2003-08-18 2005-02-24 The Bio Balance Corporation A stable liquid probiotic composition, preparation and applications thereof
WO2005017095A3 (en) * 2003-08-18 2005-07-07 Bio Balance Corp A stable liquid probiotic composition, preparation and applications thereof
JP2007518693A (en) * 2003-08-18 2007-07-12 ザ バイオ バランス コーポレイション Stable liquid probiotic composition, its preparation and application
US8399238B2 (en) 2004-03-24 2013-03-19 Nestec S.A. Shelf-stable product with living micro-organisms
WO2007136719A2 (en) * 2006-05-18 2007-11-29 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
WO2007136719A3 (en) * 2006-05-18 2008-05-29 Bio Balance Corp Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
EP2463382A1 (en) 2010-12-07 2012-06-13 Enterologics, Inc. Method for identifying E. Coli M-17
KR20150036698A (en) * 2012-07-20 2015-04-07 프레브테크 마이크로비아 인코포레이티드 Non-Pathogenic F18 E. Coli Strain and Use Thereof
EP2875121A4 (en) * 2012-07-20 2016-01-13 Prevtec Microbia Inc Non-pathogenic f18 e. coli strain and use thereof
US9453195B2 (en) 2012-07-20 2016-09-27 Prevtec Microbia Inc. Non-pathogenic F18 E. coli strain and use thereof
US10258654B2 (en) 2012-07-20 2019-04-16 Prevtec Microbia Inc. Non-pathogenic F18 E. coli strain and use thereof
US9775867B2 (en) 2012-07-20 2017-10-03 Prevtec Microbia Inc. Non-pathogenic F18 E. coli strain and use thereof
KR102171028B1 (en) 2012-07-20 2020-10-28 프레브테크 마이크로비아 인코포레이티드 Non-Pathogenic F18 E. Coli Strain and Use Thereof
US10265350B2 (en) 2012-09-25 2019-04-23 Universidad De Leon Probiotic and prebiotic compositions
US11389490B2 (en) 2012-11-23 2022-07-19 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10864235B2 (en) 2012-11-23 2020-12-15 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP4233545A3 (en) * 2012-11-23 2023-10-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11464812B2 (en) 2012-11-23 2022-10-11 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11458173B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11458174B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3628161A1 (en) * 2012-11-23 2020-04-01 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2953472A4 (en) * 2012-11-23 2017-03-01 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9855303B2 (en) 2013-02-04 2018-01-02 Seres Therapeutics, Inc. Compositions and methods
US10064901B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Compositions and methods
US10967011B2 (en) 2013-02-04 2021-04-06 Seres Therapeutics, Inc. Compositions and methods
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US11185562B2 (en) 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
US11730775B2 (en) 2013-02-04 2023-08-22 Seres Therapeutics, Inc. Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
US10064900B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US11058681B2 (en) 2013-03-14 2021-07-13 Maregade RX Product and method for treating diarrhea
US10881696B2 (en) 2013-03-15 2021-01-05 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US11666612B2 (en) 2013-03-15 2023-06-06 Seres Therapeutics, Inc Network-based microbial compositions and methods
US11918612B2 (en) 2013-11-25 2024-03-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11266699B2 (en) 2013-11-25 2022-03-08 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US11419868B2 (en) 2016-12-23 2022-08-23 White Sands Pharma Llc Low dose product and method for treating diarrhea
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CN110004072A (en) * 2018-11-12 2019-07-12 西安交通大学 One plant of probiotic enterococcus faecalis separation strains A3-1 and its application
CN113652340A (en) * 2021-08-24 2021-11-16 江苏江大源生态生物科技股份有限公司 Probiotic preparation, strain screening device and screening method
RU2785174C1 (en) * 2022-02-18 2022-12-05 Федеральное государственное бюджетное учреждение науки Пермский федеральный исследовательский центр Уральского отделения Российской академии наук (ПФИЦ УрО РАН) Probiotic for the prevention and correction of gastrointestinal diseases of farm animals and poultry

Also Published As

Publication number Publication date
MXPA03004851A (en) 2004-05-04
RU2281326C2 (en) 2006-08-10
IL156213A0 (en) 2003-12-23
WO2002043649A3 (en) 2002-08-29
EP1343370A2 (en) 2003-09-17
AU2002221004B2 (en) 2007-01-25
JP2004534512A (en) 2004-11-18
CN1294253C (en) 2007-01-10
AU2100402A (en) 2002-06-11
ZA200304747B (en) 2004-09-03
EP1343370A4 (en) 2004-02-11
NZ526748A (en) 2006-03-31
WO2002043649A8 (en) 2004-04-29
PL366363A1 (en) 2005-01-24
CN1494374A (en) 2004-05-05
CA2430292A1 (en) 2002-06-06
BR0116178A (en) 2003-10-14
KR20030082549A (en) 2003-10-22
JP4410992B2 (en) 2010-02-10

Similar Documents

Publication Publication Date Title
US6503505B2 (en) Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
AU2002221004B2 (en) Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
AU2002221004A1 (en) Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
US7504251B2 (en) Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
AU2007201690A1 (en) Preparation of Compositions Comprising Bacterial Strains and Volatile Plant Extracts and Therapeutic and Industrial Applications Thereof
NZ544366A (en) Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/004851

Country of ref document: MX

Ref document number: 156213

Country of ref document: IL

Ref document number: 2430292

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002545628

Country of ref document: JP

Ref document number: 1020037007337

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003/04747

Country of ref document: ZA

Ref document number: 200304747

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001998302

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 526748

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2003119151

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 2002221004

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018214851

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001998302

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037007337

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10432346

Country of ref document: US

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 23/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

WWP Wipo information: published in national office

Ref document number: 526748

Country of ref document: NZ